Osteocytes control myeloid cell proliferation and differentiation through GSα-dependent and -independent mechanisms by Azab, Ehab
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2018



















OSTEOCYTES CONTROL MYELOID CELL PROLIFERATION AND  
 














Bachelor of Dental Medicine and Surgery (BDS). King Abdulaziz University 2008 
Master of Science (MS). Tufts University 2015 





Submitted in partial fulfillment of the requirements for the degree of 
 
Doctor of Science in Oral Biology  














First Reader _______________________________________________________________ 
Paola Divieti Pajevic. MD, PhD 






Second Reader _____________________________________________________________ 
Makoto Senoo. PhD 















Department Chair: __________________________________________________________ 
David Levin. PhD 







This work is dedicated to my beloved family: 
 
My parents,  
Makkyah and Talal,  
my first teachers in life  
For their unconditional love, help, support, encouragement and prayers  
 
My wife,  
Reham, 
For her continuous love, support and encouragement  
For her efforts in taking care of our children while I was busy 
 
My siblings, 
Ominyah, Eman, Amjad, Ehda, Abdulrahman and Abdulaziz 
For their continuous love and prayers  
 
My daughters,  
Lameer and Lana,  






This dissertation could not be possible and completed without assistance and contribution of many 
individuals whom I am much thankful. I would like to thank the Department Chair of Molecular 
and Cell Biology Dr. David Levin and the Director Dr. Philip Trackman for accepting me as a 
student and giving me the chance to complete my doctorate.  
 
I would like to express my thanks and gratitude to my supervisor Dr. Paola Divieti Pajevic for 
giving me a chance to work in her laboratory, for her continuous mentorship and guidance through 
all the three years, for being always available for teaching and helping me. This work could not 
have been done without her advice and support. 
 
I am thankful to my committee members, Dr. Makoto Senoo, Dr. Philip Trackman and Dr. Manish 
Bais for their valuable input, guidance, and support during my thesis project.  
 
Also, I would extend my thanks to Dr. Divieti Pajevic lab's members: Yuhei Uda, Ningyuan Sun, 
Keertik Fulzele for their advice and assistance.   
 
I would like to thank the Center for Biomedical Mass Spectrometry members, Dr. Mark McComb, 
Dr. Kevin Chandler and Dr. Catherine Costello for their help in our Mass Spectrometry analysis. 
I would like to thank Dr. Amira Hussein in Dr. Gerstenfield lab for her help with IPA analysis. I 





OSTEOCYTES CONTROL MYELOID CELL PROLIFERATION AND DIFFERENTIATION 
THROUGH GSα-DEPENDENT AND -INDEPENDENT MECHANISMS 
 
EHAB AZAB 
Boston University, Henry M. Goldman School of Dental Medicine 
 




Introduction: Previous studies have shown that osteocytes, the matrix-embedded cells in bone, 
control bone modeling and remodeling through direct contact with adjacent cells and via secreted 
factors that can reach cells in the bone marrow microenvironment (BMM). Osteocytes express 
several receptors including G protein-coupled receptors (GPCRs) and mice lacking the stimulatory 
subunit of G-proteins (Gsα) in osteocytes have abnormal myelopoiesis, skeletal abnormalities and 
reduced adipose tissue. This study aimed at evaluating the effects of osteocyte-secreted factors on 
myeloid cell proliferation and differentiation in vitro. To investigate cross-talk between osteocytes 
and the BMM, we established osteocytic cell lines lacking Gsα expression to study the molecular 
mechanisms by which osteocytes control myeloid cell proliferation and differentiation.  
Methods: CRISPR/Cas9 was used to knockout Gsα in the osteocytic cell line Ocy454. 
Conditioned media (CM) from differentiated Ocy-GsαCtrl and Ocy-GsαKO cells were used to treat 
myeloid cells and bone marrow mononuclear cells (BMNCs) isolated from long bones of 6-8-
 vii 
week-old C57/BL6 mice. BMNCs were cultured with Macrophage Colony Stimulating Factor (M-
CSF), Receptor Activator of Nuclear Factor Kappa b Ligand (RANKL) to induce osteoclast 
differentiation. Proliferation, TRAP staining, TRAP activity, resorption pit assay, F-actin ring 
formation and mRNA expression were used to evaluate cell proliferation, differentiation and 
function of the induced osteoclasts. Proteomics analysis of CM was performed to identify 
osteocyte-secreted factors capable of controlling myelopoiesis and osteoclastogenesis.  
Results: Myeloid cells treated with CM from Ocy-GsaKO showed a significant increase in cell 
proliferation compared to Ocy-GsaCtrl CM and non-treated control. BMNCs treated with CM from 
Ocy-GsaCtrl and Ocy-GsaKO showed a significant increase in cell proliferation as compared to 
non-treated control. Osteoclast differentiation was significantly suppressed by CM from Ocy-
GsaCtrl and further suppressed by CM from Ocy-GsaKO compared to non-treated control. 
Osteoclasts exposed to CM from Ocy-GsaKO showed a significant defect in activity and function 
as compared to cells exposed to CM from Ocy-GsaCtrl and non-treated cells. Osteoclast apoptosis 
was significantly enhanced by Ocy-GsaCtrl and Ocy-GsaKO CM compared to non-treated control. 
Among osteocyte secreted factors, we identified neuropilin-1 (NRP-1) as a Gsa-dependent 
osteocytic factor capable of suppressing osteoclastogenesis. CM from Ocy-GsaKO in which M-
CSF was reduced by shRNA demonstrated decrease in BMNCs proliferation, demonstrating that 
osteocytes are also important sources of this cytokine.  
Conclusions: Osteocytes produce several Gsa-dependent and -independent secreted factors 
capable of supporting myelopoiesis, promoting macrophage proliferation and suppressing 
osteoclast formation. We identified osteocyte-derived NRP-1 as a novel factor capable of 
decreasing osteoclastogenesis. In addition, we found that M-CSF secreted by osteocytes is 
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Bone and bone cells 
Bone is a specialized connective tissue comprised of cells and calcified extracellular matrix. Bone 
extracellular matrix consists of organic and inorganic components. The organic components 
include collagen (mainly type I) and non-collagenous proteins, including osteocalcin, osteopontin, 
osteonectin, bone sialoprotein II, and bone morphogenic proteins (BMPs). The inorganic 
components consist mainly of calcium and phosphate and traces of other minerals, including 
sodium, potassium, magnesium, fluoride, and bicarbonate (1). The skeleton has four main 
functions: providing surfaces for muscles attachment, protection of vital organs, providing a source 
of calcium and phosphate needed for mineral homeostasis (2, 3), and serves as the primary site of 
postnatal hematopoiesis (4).  
Bone is a highly dynamic tissue with a remarkable regenerative capacity for repair and 
reshape in response to mechanical loading or injury. Bone modeling involves bone formation 
without prior resorption or bone resorption without bone formation (uncoupled process). Bone 
modeling occurs in children during growth, leading to an increase in bone size and length 
according to genetic and adaptive responses to loading. Bone remodeling, on the other hand, 
involves the coupling of bone formation and resorption mediated by osteoblasts and osteoclasts, 
respectively. Bone remodeling occurs throughout the entire human lifespan, including adulthood, 
and is required for maintaining bone structural integrity. Imbalance in bone remodeling can result 
in osteopenia or osteoporosis. Bone remodeling is regulated by several systemic factors 
(parathyroid hormone (PTH), estrogens, calcitonin) and by local factors (growth factors and 




Bone has three major cell types: osteoblasts, osteocytes, and osteoclasts. Osteoblasts form 
bone matrix whereas osteoclasts resorbs it (7, 8). Osteoblasts are derived from mesenchymal stem 
cells and localize on the surface of bones where they function to secrete bone matrix which is 
subsequently mineralized. Osteoblasts express alkaline phosphates and secrete type I collagen and 
non-collagenous proteins to generate non-mineralized osteoid (9, 10). The fate of osteoblast after 
matrix formation is either to die by apoptosis, to become a quiescent bone lining cell or to become 
an osteocyte by being entrapped deep in the matrix and changing its morphology (11). Osteocytes 
are bone cells that are deeply embedded within the mineralized matrix of bone. Recently, 
osteocytes were shown to function as a master regulator of bone modeling and remodeling; 
additionally, osteocytes control the activity of osteoblasts and osteoclasts by direct cell-to-cell 
contact and via secreted factors (8, 12).  
 
Osteocytes 
Origin, differentiation and morphology of osteocytes 
Osteocytes are the most abundant cell type in the adult skeleton, accounting for 90-95% of bone 
cells (20,000 – 80,000 cells/ mm3 bone tissue). Osteocytes have the longest lifespan of all bone 
cells; in humans, it has been estimated that osteocytes can live up to 25 years (13, 14). Osteocytes 
differentiate from osteoblasts that are derived from mesenchymal stem cells. The transition from 
osteoblasts to osteocytes is characterized by extensive changes in cell morphology and internal 
organelles (morphology changes from a polygonal shape to a stellate shape) (2, 7, 15). During this 
transition, osteocytes go through various stages of differentiation and are classified as osteoid, 





Bone matrix surrounding newly formed osteocytes is gradually mineralized. As 
mineralization progresses, organelles and cytoplasmic volume of osteoid osteocytes and mature 
osteocytes are reduced by 30% and 70%, respectively (2). Osteoid osteocytes are characterized by 
their proximity to endosteal surfaces and downregulation of bone sialoprotein (BSP), collagen type 
I (COL1), alkaline phosphatase (ALP), osteocalcin, and Runt-related transcription factor 2 
(RUNX2). In contrast, expression of the following osteocyte-specific markers is upregulated: 
E11/gp38/podoplain, matrix extracellular phosphoglycoprotein (MEPE), phosphate regulating 
endopeptidases homolog X-linked (PHEX), and dentin matrix protein-1 (DMP1). In addition to 
osteoid osteocyte markers, mature osteocytes express sclerostin (encoded by the SOST gene) and 
fibroblast growth factor-23 (FGF23) (7, 16). 
Osteocytes localize in lacunae within the mineralized matrix and extend their dendritic 
processes within tiny canaliculi that connect the lacunae. These dendrites range from 40 to 100 per 
cell and connect the cells with other osteocytes. The presence of numerous dendritic processes 
allows osteocytes to contact and communicate with bone lining cells and osteoblasts from one side 
and capillaries and vessels from another side. Some of these dendritic processes extend deep into 
the bone marrow space, which may allow for regulation of bone marrow cells. This network of 
canaliculi and lacunae is termed the lacuna-canalicular system. The space between dendritic 
processes and their canaliculi is filled with lacunocanalicular fluid that carries essential nutritional 
factors and oxygen required to maintain cell viability in this enclosed system (8). 
 
Osteocyte function 
Osteocytes have several functions including mechanosensation, mechanotransduction, control of 





Osteocytes-mediated mechanosensation and mechanotransduction 
Bone is designed to withstand a high magnitude of loads. For instance, the approximate 
compressive strength of human femur is 100 megapascal (MPa) (17, 18). Prolonged bed rest, space 
flight, or paralysis are accompanied by skeletal fragility and rapid bone loss, while increased loads 
result in increased bone strength (19). The most accepted theory of osteocyte mechanosensation is 
that mechanical loading of the skeleton induces deformity in the bone matrix, which increases the 
fluid flow in the lacunocanalicular system to create fluid flow shear stress (FFSS), stimulating 
osteocytes (8, 20). Several mechanisms have been proposed explaining how osteocytes sense 
loading. Integrins, cilia, calcium channels, and G protein coupled receptors (GPCRs) were 
identified as possible mechanosensors (21, 22). Recently, the cytoskeletal protein Spectrin was 
identified as a mechanosensitive molecule in osteocytes (23). Other potential mechanosensors 
include ephrins, gap junctions, connexin 43 (CX43), hemichannels, and ion channels (24, 25). 
Once a signal is perceived by osteocytes, it needs to be converted into biological stimuli. 
Osteocytes respond to mechanical loading by increasing intercellular calcium and releasing ATP. 
In vivo treatment with calcium channel blockers reduces the skeletal response to mechanical 
loading (24, 26). ATP rapidly increases upon mechanical loading and in vitro studies suggest that 
calcium is required for ATP response (27). Wnt activity increases upon mechanical loading. 
Studies have shown that mice lacking catenin in osteocytes have severe bone loss and die 
prematurely whereas catenin heterozygote mice have impaired responses to mechanical 
loading (28).  
Osteocytes secrete several factors in response to mechanical loading, including 




of osteocytes to mechanical loading. PGE2 activates E2-E4 receptors in an autocrine or paracrine 
fashion leading to an increase in intracellular ATP and activation of protein kinase A (PKA). 
Osteocytes release NO that inhibits bone resorption and promotes bone formation in response to 
mechanical loading or fluid flow shear stress (FFSS) (7, 25, 29, 30). Conversely, expression of 
sclerostin decreases upon loading and increases during hind limb unloading (31). Furthermore, 
SOST-deficient mice are resistant to bone loss induced by hind limb unloading (32). Lastly, it has 
been shown that osteocytes are the main source of insulin-like growth factor 1 (IGF-1), which is 
required for appropriate anabolic responses to mechanical loading (33). Mice lacking IGF-1 in 
osteocytes show blunted anabolic responses to mechanical loading, suggesting that IGF-1 is an 
important regulator of bone homeostasis (34).  
 
Osteocytes and bone remodeling  
Osteocytes orchestrate bone modeling and remodeling by controlling osteoblast and osteoclast 
activities (7, 35, 36). Osteocytes have been shown to regulate osteoblasts by releasing factors such 
as NO, PGE2 and sclerostin, as described above. In vivo studies have shown that osteocytes release 
NO in response to mechanical loading, which leads to bone formation (37). NO has been shown 
to induce osteoblast differentiation in vitro (38). PGE2 released from osteocytes has been shown 
to increase bone mass in vivo and to induce osteoblast differentiation and bone formation in vitro 
(39, 40). Sclerostin, the product of the SOST gene, is synthesized and secreted by osteocytes and 
inhibits osteoblast proliferation and differentiation via inhibition of the canonical Wnt signaling 
pathway. Mechanical unloading and space flight have been shown to increase sclerostin leading 




sclerostin and promote bone formation (32). In recent clinical trials, anti-sclerostin antibodies have 
been shown to reduce the risk of bone fracture in postmenopausal women with osteoporosis (44). 
In adult skeleton, osteocytes are the primary source of Receptor Activator of Nuclear 
Factor Kappa B Ligand (RANKL), which is essential for osteoclast differentiation. This cytokine 
binds to the RANK receptor expressed on osteoclast precursors (35, 45). Osteoprotegerin (OPG) 
is also secreted by osteocytes and inhibits osteoclastogenesis by binding to RANKL, thereby 
inactivating RANKL (46-48). Deletion of RANKL in osteocytes in mice results in osteopetrosis 
(35). Interestingly, these mice are protected from osteopenia when subjected to hind limb 
unloading, suggesting that osteocyte-derived RANKL plays a critical role in disuse-induced bone 
loss (36).  Furthermore, in vitro studies have shown that osteocytes exposed to mechanical forces 
secrete matrix extracellular phosphoglycoprotein (MEPE) that upregulates OPG and decreases the 
RANKL/OPG ratio that leads to osteoclast inhibition (49), while unloading conditions increase 
RANKL expression (42). Mice with -catenin deficiency in osteocytes display increased 
osteoclastogenesis due to a decrease in OPG expression (50). Under physiological conditions, 
viable osteocytes secrete factors that inhibit osteoclast activity, while apoptotic osteocytes 
stimulate osteoclast activity (51). Indeed, in vivo deletion of osteocytes, using the diphtheria toxin 
receptor, stimulates osteoclast activation (52). In vitro studies have shown that osteocytes secrete 
transforming growth factor  (TGF-), which inhibits osteoclastogenesis; additional inhibition of 
osteoclastogenesis is observed with pretreatment of osteocytes with estrogen (53). Osteocytes have 
been shown to secrete IFN- (54, 55) and mice lacking interferon- (IFN-) are osteoporotic, 





Osteocytes regulate mineral homeostasis 
Osteocytes secrete proteins which play important roles in phosphate homeostasis, such as DMP1, 
PHEX, MEPE, and FGF-23 (24, 30). DMP1 is a regulator of mineralization and DMP1-deficient 
mice have hypophosphatemia and high levels of FGF-23, leading to osteomalacia. Similarly, 
patients with a mutated form of DMP1 display autosomal recessive hypophosphatemic rickets 
(56). In contrast, overexpression of DMP1 lead to an increase in mineral density (57). PHEX is 
another protein involved in phosphate hemostasis. Mutations in the PHEX gene result in X-linked 
hypophosphatemic rickets. Hyp mice, a model for X-linked hypophosphatemic rickets, have an 
impaired mineral balance and have increased levels of FGF23 (58).  
MEPE is secreted by osteocytes and contributes to phosphate hemostasis. MEPE deficient 
mice have a progressive increase in mineral apposition with aging (59). MEPE is cleaved by 
cathepsin B or D then releases an acidic serine aspartate-rich MEPE associated motif (ASARM) 
peptide that antagonizes PHEX, which in turn inhibits matrix mineralization and elevates FGF-23 
levels (60-62). The previous in vivo study showed that administration of MEPE in rats led to an 
increase in phosphate excretion. Consistent with this finding, in vitro administration of 
recombinant MEPE to renal cells prevented phosphate uptake (63). Hyp mice - Phex deficient 
mouse model - have high serum levels of MEPE-ASARM (acidic serine aspartate-rich MEPE 
associated motif) as well as high FGF-23 levels (64). DMP1, MEPE, and PHEX are regulators of 
FGF-23. Osteocytes produce FGF-23 and this hormone binds to its receptor FGFR1- Klotho in the 
kidneys and the parathyroid gland; thus, signaling between the kidneys, parathyroid gland, and 





G-Protein coupled receptors (GPCRs) signaling in osteocytes 
GPCRs are a family of eukaryotic-specific receptors. GPCRs contain seven transmembrane 
domains and are coupled with heterotrimeric G-proteins. GPCRs detect extracellular signals from 
hormones, chemokines, and neurotransmitters and transduce them into cellular actions. GPCRs 
are involved in many physiological mechanisms including regulation of taste, vision, smell, 
sympathetic and parasympathetic nervous system, immune system, homeostasis, bone 
development, and hematopoiesis (67). 
G-proteins consist of three subunits (,  and ), which bind to guanosine diphosphate 
(GDP) in their inactive state. There are 20 G, 6 G, and 11G subunits that have been identified, 
so far. In response to extracellular stimuli, GPCRs undergo conformational changes and exchange 
GDP to guanosine triphosphate (GTP), leading to the activation of G and its dissociation from 
the dimeric G. Gs is encoded by exons 1-13 of the GNAS gene. The GNAS locus is located on 
chromosome 20 in humans whereas in mice it is located on chromosome 2. GNAS structure in 
humans and mice is very similar. Other products encoded by GNAS include extra-large Gs (Xls) 
and neuroendocrine secretory protein-55 (NESP-55). These transcripts contain a unique exon 1 
that splices to exons 2-13 in the GNAS gene (68, 69). Gs main function is to activate adenylate 
cyclase. Adenylate cyclase catalyzes the conversion of adenosine triphosphate (ATP) to cyclic 
adenosine monophosphate (cAMP), which activates protein kinases involved in the regulation of 
gene expression and cellular responses (67, 70). Signaling through GPCRs in osteocytes is 
necessary for bone development, bone remodeling, and hematopoiesis (70-72) (Figure 1). 
Parathyroid hormone (PTH) receptor type 1 (PTH1R), prostaglandin receptor (PGE2), and 
-adrenergic receptor are some of the Gs-coupled receptors abundantly expressed by osteocytes 




bone structure and high sclerostin expression. These mice also did not respond to PTH treatment, 
demonstrating that PTH1R is important in bone homeostasis (73). Another study reported that 
PTH1R signaling in osteocytes is important for proper osteoblast and osteoclast function and that 
deletion of PTH1Rin osteocytes resulted in impairment of bone remodeling (75).  
Osteocytes produce PGE2 in response to mechanical loading (74). PGE2 functions as an 
autocrine factor that activates E2-E4 receptors expressed by osteocytes. In addition, PGE2 also acts 
as a paracrine factor that modulates osteoblast and osteoclast functions. Signaling through 
prostaglandin (E2-E4) receptors is important for osteocyte communication and responses to 
mechanical loading (25, 76). The -adrenergic receptor is another class of Gs-coupled receptor. 
This receptor is expressed by osteocytes and supports osteoclastogenesis through -adrenergic 
signaling (77). Another study showed that tail suspension in mice induced changes in the 
cancellous bone structure and promoted osteocytes apoptosis. However, treatment with 
isopropanol, a non-selective -adrenergic receptor agonist, was able to reduce the effect of tail 
suspension on cancellous bone structure and protected osteocytes from apoptosis (78). 
It has been previously reported that mice lacking Gsα in osteocytes (DMP1-GsαKO) 
display skeletal abnormalities, including a significant decrease in cortical and trabecular bone 
volume, bone mineral density, and bone mineral content. Osteoblast numbers were significantly 
reduced both in young and adult mice. Serum levels of bone formation markers (procollagen type 
I N propeptide (PINP) and osteocalcin) were significantly suppressed in DMP1-GsαKO mice 
compared to littermate controls. These findings suggest that osteopenia was mainly driven by 
suppression of bone formation. Also, these mice had a significantly increased levels of sclerostin, 
a potent Wnt signaling inhibitor produced mainly by osteocytes. These mice also display 




peripheral blood while lymphoid cells were not affected (72). Administration of anti-sclerostin 
antibodies was able to rescue osteoblast numbers and normalize the skeletal phenotype but not the 
















Figure 1: Schematic representation of GPCR signaling pathway.  
Upon responses to extracellular stimuli, GPCR undergoes conformational changes and exchanges 
Guanosine diphosphate (GDP) to guanosine triphosphate (GTP) leading to the activation of G 
and dissociation from the dimeric G that activates adenylate cyclase. Adenylate cyclase enzyme 
catalyzes adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP) which 





















Bone has a critical role not only in support, protection and forming body structure but also in 
maintaining microenvironment for many cell types. The presence of bone marrow within bone 
cavities suggests a physiological interaction between these two tissues. Hematopoiesis is the 
process of constant generation of blood cells. Before birth, hematopoietic stem cells (HSCs) 
migrate from the fetal liver to the bone marrow. Postnatally, bone marrow becomes the site of 
hematopoiesis, which begins with a small population of self-renewing HSCs that give rise to 
transit-amplifying cells with high proliferation rates but reduced proliferative potential compared 
with HSCs. Transit-amplifying cells then give rise to either common myeloid progenitors (CMP) 
or common lymphoid progenitors (CLP). While CMP produce neutrophils, eosinophils, basophils, 
monocytes (including macrophages and osteoclasts), erythrocytes, and platelets, CLP give rise to 
T- lymphocytes, B- lymphocytes, and natural killer cells (Figure 2). These processes are highly 
controlled by the interaction between bone marrow cells and the endosteal bone surface (4, 80-
83). 
HSCs reside in a highly organized environment called “niche” that maintains a dynamic 
balance between self-renewal and differentiation of HSCs. The HSC niche is complex and consists 
of mesenchymal-lineage cells, including osteoblasts, fibroblasts, adipocytes, vascular endothelial 
cells, and hematopoietic cells comprised of monocytes, macrophages, and osteoclasts. Signals 
derived from these cells regulate the maintenance and regeneration of HSCs. Therefore, it is 
reasonable to see that dysfunction of HSC niche contributes to hematopoietic diseases (4, 80, 84).  
Under physiological conditions, approximately 0.06% of HSCs circulate in the 
bloodstream (85). However, numerous molecules can induce mobilization (or homing) of HSCs 




interleukin-8, stem cell factor (SCF)/Kit ligand and chemokines, and stromal-derived factor 1 
(SDF-1) (86, 87) (also known as CXCL-12) are among the factors capable of controlling HSC 
mobilization. SDF-1 is expressed in stromal cells and binds to its receptor CXCR-4 expressed in 
HSCs, thereby anchoring HSCs within the niche. Indeed, mice lacking SDF-1 have defects in HSC 
mobilization (88, 89). N–cadherin and signaling through Angiopoietin-1 and its receptor tyrosine 
kinase (Tie-2) are also necessary for the maintenance of HSC homing in bone marrow (84, 90). 
HSCs express several adhesion molecules important for homing including, but not limited to, very 
late antigen-4 (VLA-4) and its ligand vascular cell adhesion molecule (VCAM), leukocytes 
function antigen-1 (LFA-1), and 41 integrin (88, 91, 92). Osteopontin is another factor that keeps 
HSC homing in marrow and osteopontin- deficient mice showed HSC mobilization from the 
marrow to the periphery (93, 94).  
G-CSF has been widely used as a treatment for cancer patients. After chemotherapy, cancer 
patients suffer from immune deficiency including the lack of myeloid lineage cells. G-CSF 
administration is widely used to induce myeloproliferation and mobilization of HSCs to the 
bloodstream (95, 96). G-CSF works by lowering the expression level of SDF-1 in the bone marrow 
and inducing production of matrix metalloproteinase (MMP-9 and MMP-2) and other proteolytic 
enzymes, which then release stem cell factor (Kit ligand) from its receptor (c-Kit) and mobilize 
HSCs (86-88, 97, 98). CD44 is an adhesion molecule important in homing and mobilization of 
HSCs. Indeed, mice with CD44 deficiency display an impairment in HSC mobilization in response 
to G-CSF treatment (99). Furthermore, some growth factors, such as vascular endothelial growth 








Figure 2: Schematic representation of hematopoiesis. 
Hematopoiesis begins with a small population of life-long self-renewing long-term HSCs (LT-
HSC) giving rise to short-term HSCs (ST-HSC), which gradually lose lineage differentiation 
potential and become multipotent progenitors (MPP). These transit-amplifying cells give rise to 
either common myeloid progenitors (CLP) or common lymphoid progenitors (CMP). Further, 
while CLP generate T- lymphocytes, B- lymphocytes and natural killer cells, CMP produce 
neutrophils, eosinophils, basophils, monocytes, erythrocytes and platelets. Monocytes become 
macrophages and osteoclasts in peripheral tissues and bones, respectively.  This figure was adapted 
from Baldridge, M.T., K.Y. King, and M.A. Goodell, Inflammatory signals regulate hematopoietic 
stem cells. Trends Immunol, 2011. 32(2): p. 57-65. 
 
 
Bone cells and hematopoiesis 
Previous studies suggested that osteolineage cells are important regulators of hematopoiesis. The 
expression of a constitutive active (ca) PTH receptor (PTH1R) in osteoblasts increased HSCs via 





of Gsα signaling in osteoblasts induced a decrease in B lymphopoiesis through a reduction in 
interleukin-7 expression (71). Similarly, osteoblast deficiency in mice led to the loss of HSCs as 
well as the progenitors of lymphoid, erythroid, and myeloid lineages (101). Signaling through the 
2-adrenergic receptor in osteoblasts was shown to induce HSC mobilization by upregulating the 
vitamin D receptor (102). Also, hypoxic osteoblasts play a role in the regulation of erythropoiesis 
and function as osteoblasts are major producers of erythropoietin (103).  
Osteoclasts were shown to regulate HSC niche. RANKL treated mice display an increase 
in osteoclastic activity, leading to a moderate increase in HSC mobilization (104). Moreover, 
endosteal macrophages (osteomac) play a role in supporting osteoblasts; reduction of these 
specialized macrophages by G-CSF injection reduced osteolineage cells and promoted 
mobilization of HSCs (105, 106). Other studies suggested that macrophages may release factors 
capable of supporting osteolineage cells, which in turn regulate the HSC niche (107).  
The role of osteocytes and Gsα signaling in HSC regulation is not well understood. 
Previous studies have shown that expression of a constitutive active (ca) PTH1R in osteocytes 
does not affect HSCs (73, 108). To better understand the role of osteocytes and Gsα signaling in 
hematopoiesis, our group generated transgenic mice in which osteocytes lack expression of Gsα 
by crossing Gs flox/flox mice with DMP1-Cre mice (72). These mice display both skeletal 
abnormalities (i.e. severe osteopenia) and hematopoietic defects (i.e. neutrophilia, thrombocytosis, 
and leukocytosis in bone marrow, spleen, and peripheral blood) while lymphoid cells were not 
affected. Bone marrow transplantation from control mice to lethally irradiated Gsα knockout mice 
induced myeloproliferation, while the reverse experiment normalized the hematopoietic profile, 
indicating that this abnormality was due to extrinsic factors secreted from osteocytes. Moreover, 




enriched bone explant (OEBE), it has been reported that OEBE-CM from Gsα KO mice induce a 
significant increase in myeloid cell number, demonstrating that osteocytes secrete factors capable 
of supporting myeloid proliferation and that these factors are Gsα dependent (72). 
 
Osteoclasts 
Osteoclast origin and differentiation 
Bone resorption is essential for bone modeling, remodeling, fracture healing, calcium homeostasis, 
and tooth eruption. Osteoclasts are the bone cells responsible for resorbing bone. Osteoclasts are 
multinucleated cells derived from HSCs specifically from monocytes/macrophages of myeloid 
lineage. Overstimulation of osteoclasts results in several human disorders including osteoporosis, 
rheumatoid arthritis, and periodontal diseases. Also, defects in osteoclast activity result in 
osteopetrosis. Osteoclasts are located in resorption pits/depressions on the bone surface called 
Howships lacunae, which are believed to form as a result of degradation of the underlying bone. 
Osteoclasts are characterized by foamy cytoplasm due to the presence of vesicles and lysosomes 
filled with acid phosphatase (109, 110).  
Macrophage colony stimulating factors (M-CSF) and RANKL are two key factors needed 
for osteoclast formation and differentiation. M-CSF binds to the colony stimulating receptor-1 
(CSFR-1; also known as c-fms) expressed on osteoclast precursors and induces proliferation and 
differentiation of pre-osteoclasts. RANKL, which is expressed by mesenchymal cells such as 
osteoblasts and osteocytes, is essential for multinucleated cell differentiation and fusion. RANKL 
binds to the Receptor Activator of Nuclear Factor Kappa  (RANK) present on osteoclast 
precursors and induces cell fusion and formation of mature multinucleated osteoclasts. 




and cytokines, including PTH, tumor necrosis factor- (TNF-), 1,25 dihydroxyvitamin D3, 




Bone resorption by osteoclasts involves multiple processes, starting with the migration of 
osteoclasts to the resorption site by chemotaxis. Once osteoclasts reach the resorption area they 
attach to the bone surface and form the sealing zone. This zone is rich in filamentous actin (F-
actin) that is localized in plasma membrane protrusions called podosomes, which form a ring/belt 
structure surrounding the resorption site (109, 111). The sealing zone contains proteins such as 
vinculin, talin, and -actin that help to link v3 integrin on osteoclasts with RGD sequence 
proteins (Arg-Gly-Asp) on the bone surface such as osteopontin, bone sialoprotein, and vitronectin 
(118, 119). v3 integrin plays a critical role in osteoclast function and v3 antagonists result in 
osteoclast dysfunction (120).  
The interaction between integrins and resorption surfaces facilitates osteoclast polarization 
by reorganizing the cytoskeleton to form the ruffle border structure. The ruffle border faces the 
resorption site and contains a vacuolar-type H+–adenosine triphosphate (H+-ATPase) proton pump 
capable of moving hydrogen ions against the concentration gradient. The source of hydrogen ions 
is carbonic acid that is generated from carbon dioxide and water by the action of the cytoplasmic 
carbonic anhydrase. To maintain electroneutrality, chloride ions are transported through chloride 
channels to the resorption compartment and then combine with protons in the ruffle border 
membrane to form hydrochloric acid (HCl) that is released by osteoclasts to acidify the resorption 




taken by vesicles moving across the cells to the anti-resorptive site and then are released into the 
extracellular fluid (110, 111, 121). 
Several hydrolytic enzymes mainly cathepsin K and matrix metalloproteinase-9 (MMP-9) 
are secreted by lysosomes from the ruffle border into the resorption site, leading to the digestion 
of organic components of the bone matrix (122, 123). Collagen fragments within intercellular 
vesicles are taken to osteoclasts by endocytosis for further digestion by reactive oxygen species 
generated by tartrate-resistant acid phosphatase (TRAP) enzyme in a process called transcytosis. 
Bone resorption ends either by osteoclast apoptosis or quiescence (124, 125).   
 
Factors involved in regulation of osteoclast formation 
Many factors have been shown to regulate osteoclast differentiation and functions. M-CSF and 
transcription factor PU-1 are required for proliferation and survival of osteoclast precursors.  Mice 
lacking M-CSF display osteopetrotic phenotype (126). PU-1 mutant mice also present with 
osteopetrosis, demonstrating that these factors are essential for osteoclast formation and function 
(127). RANKL, RANK, TNF receptor association factor 6 (TRAF-6), c-Fos, Nuclear factor of 
activated T cells cytoplasmic 1 (NFATc1), Nuclear factor kappa light chain enhancer of activated 
B cells (NF-κB), I kappa B kinase (IKK), DNAX- activating protein (DAP-12) and Fc receptor 
common gamma chain (FcR) are needed for osteoclast differentiation and loss or inactivation of 
these proteins results in osteoclast inhibition and osteopetrosis (128-135). Additional factors have 
been implicated in osteoclast fusion such as dendritic cell specific transmembrane protein (DC-
STAMP) and ATPase, H+ transporting lysosomal V0 subunit d2 (ATP6v0d2). Mice lacking either 
DC-STAMP or ATP6v0d2 have defects in osteoclast fusion and differentiation, but they develop 




Finally, c-Src (C-terminal tyrosine protein kinase), chloride channel 7 alpha subunit 
(CLCN7), ATPase, H+ transporting, [vacuolar proton pump] member I (ATP6i), cathepsin K, 
latent-transforming growth factor beta-binding protein 3 (LTBP-3), v3 integrin and carbonic 
anhydrase II, have been associated with osteoclast maturation and function and mutations of any 
of these genes result in reduced resorption activity (138-145). 
OPG, released by osteoblasts and osteocytes, has been recognized as a negative regulator 
of osteoclastogenesis by competitive binding to RANK receptor. Overexpression of OPG in vivo 
results in osteopetrotic phenotypes in mice while OPG-deficient mice have enhanced osteoclast 
activity and osteoporosis. (146-149)  Therefore, since OPG functions as decoy receptor for 
RANKL, the ratio between these two proteins is critical in regulating osteoclast formation and 
activity. Bone morphogenetic protein 2 (BMP-2) signaling, Wnt signaling, estrogen, calcitonin 
and transforming growth factor-  were shown to enhance OPG expression (50, 113, 146, 150, 
151). 
 
Semaphorins, originally identified in neuronal development and axon guidance, have been 
associated recently with skeletal homeostasis. Semaphorin 3A (SEMA3A) (the secreted form of 
the family) is expressed by osteoblasts and osteocytes and plays a role in bone remodeling by 
enhancing osteoblast differentiation as well as inhibiting osteoclast formation. SEMA3A deficient 
mice are osteopenic due to suppressed osteoblastic bone formation and increased osteoclastic bone 
resorption. Furthermore, in vitro treatment with SEMA3A suppressed multinucleated TRAP 
positive osteoclast number and osteoclastic gene markers expression in a dose-dependent manner. 




by inhibiting Rho signaling and immunoreceptor tyrosine-based activation motif (ITAM) signaling 
pathways (152, 153). 
 
Signaling pathways involved in osteoclastogenesis 
M-CSF is necessary for osteoclast development. M-CSF binds to the c-fms receptor and induces a 
conformational change in the receptor, which results in the activation of tyrosine kinase domains 
and stimulation of many intracellular pathways, including the mitogen activated protein kinase 
(MAPK) pathway and subsequently ERK pathway. ERK plays a key role in survival and 
proliferation of osteoclast precursors. Once ERK is activated, it translocates into the nucleus and 
increases the expression of c-fos, an essential transcription factor for osteoclast development (154). 
M-CSF activates Akt signaling that participates in osteoclast proliferation and survival (155). M-
CSF also activates microphthalmia-associated transcription factor (MIFT), which increases the 
expression of anti-apoptotic factor BCL-2 via promoter binding, thereby protecting osteoclasts 
from apoptosis (156) (Figure 3).  
RANKL/OPG/RANK is another signaling pathway required for osteoclast formation and 
differentiation. RANKL is a member of the tumor necrosis factor (TNF) cytokine family and is 
expressed either as a soluble protein or as a membrane-bound form that binds to the RANK 
receptor expressed on osteoclast precursors. The RANK receptor lacks intrinsic enzymatic activity 
and it exerts its effect by recruiting the adaptor molecule TRAF. The cytoplasmic domain of 
RANK contains five binding sites: three for TRAF6 and two for other members of the TRAF 
family (TRAF2, TRAF3 and TRAF5). Upon RANKL/RANK binding, TRAF6 undergoes a 




Akt/PI3K pathways. Grb2 associated binder 2 (Gab-2) is another adaptor molecule essential for 
RANK and RANKL signaling (113, 157, 158) (Figure 4). 
NF-κB is a group of dimeric transcription factors that recognize the κB site in DNA 
sequences. NF-κB has five family members: Rel (cRel), Rel-A (p65), Rel-B, NF-κB1(p50), and 
NF-κB2(p52). Activation of NF-κB depends on classical and alternative pathways. In unstimulated 
cells, NF-κB binds to the IκB inhibitory protein in the cytoplasm. Upon RANKL binding and 
TRAF6 activation, IκB kinase (IKK) induces phosphorylation of IκB, leading to its ubiquitin-
dependent degradation by 26S proteasome, which releases NF-κB. IKK- facilitates translocation 
of Rel-A (p65) and NF-κB1(p50) while IKK- facilitates Rel-B and NF-κB2(p52) nuclear 
translocation. NF-κB binds to the NAFTC1 promoter that controls NAFTC1 transcription to 
regulate its expression. NAFTC1 has been reported to be important in osteoclast differentiation 
(158-161) (Figure 4). 
MAPK signaling is also activated by interaction of RANK and RANKL. The MAPK 
family is comprised of p38, c-Jun N- terminal kinase (JNK 1, 2, 3), and extracellular signal 
regulated kinases (ERK1, 2). RANK/ RANKL binding activates TRAF-6 that induces MAPK 
activation (MEKK1/2, MKK4/7, and MKK3/6). Each of these enzymes has a specific target. 
MEKK1/2 phosphorylates and activates ERK1 and ERK2, while MKK4/7 activates JNK, leading 
to phosphorylation of the activator protein complex (AP-1) and its components c-fos and c-Jun. 
ERK and JNK signaling are important for osteoclast survival (162-165). On the other hand, 
MKK3/6 activates p38 signaling, which induces the mi/Mitf transcription factor that plays a role 
in controlling cathepsin K and TRAP expression required for osteoclast maturation and function 
(166, 167). RANK and RANKL signaling also activates Akt/PI3K pathway. Akt/Pi3K stimulates 




osteoclast survival and enhances integrin expression, which is necessary for osteoclast function 














Figure 3: Schematic representation of M-CSF signaling pathway involved in 
osteoclastogenesis. 
M-CSF binds to c-fms receptor and induces conformational changes of the receptors leading to 
activate tyrosine kinase domains and stimulate many intercellular pathways including MAPK 
signaling pathway and Akt signaling which is participating in osteoclast proliferation and 
survival. M-CSF signaling also activates MIFT which interacts with anti-apoptotic BCL-2 
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Figure 4: Schematic representation of RANKL/RANK signaling involved in 
osteoclastogenesis. 
Upon RANK and RANKL binding, TRAF 6 undergoes a conformational change that initiates 
many signaling pathway including NF-κB, MAPK and Akt/PI3K pathways. These pathways 
activate several transcriptional factors such as NFATC, mi/Mitf, Ap1, c-Fos and c-Jun which are 




Tools to study osteocytes 
Osteocytes are difficult to study in their physiological context due to their location deep in the 
mineralized bone matrix. However, in vitro models of osteocytes developed in our lab, coupled 
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with recent advances in gene silencing technologies, such as Clustered Regularly Interspaced Short 
Palindromic Repeats (CRISPR/ Cas9) gene editing and RNA interference (RNAi), have provided 
tools to increase our knowledge of the role of osteocytes in mechanotransduction, bone 
remodeling, and hematopoiesis.  
The development of the DMP1-Cre mouse line in which expression of Cre recombinase is 
driven by the DMP1 promoter has allowed researchers to delete the genes involved in skeletal 
metabolism to study osteocyte function. Osteocytes, odontoblasts, and late osteoblasts are the 
predominant cell types that express DMP1 (8). The Cre-loxP technique was used to generate 
transgenic mice lacking Gs in osteocytes by crossing DMP1-Cre mice with Gs flox/flox animals 
(72). 
The discovery of small interfering RNA has provided a useful genetic tool to silence genes 
for in vitro studies. The short hairpin RNA (shRNA) is one RNA interference system in which 
synthetic RNA sequences are used to silence genes of interest. shRNA can be introduced to cells 
as a form of plasmids, bacteria (Escherichia coli), or viruses (adenovirus, retrovirus, and 
lentivirus). shRNA consists of two complimentary 19-22 base pair sequences linked by 4-11 
nucleotides that form a short loop. In the cytosol, shRNA is recognized by an endoribonuclease 
enzyme called dicer which cleaves the long double-stranded RNA into short interfering RNA 
(siRNA) of 19-22 base pairs in length. siRNA is integrated with proteins to form a multicomponent 
RNA induced silencing complex (RISC). Single-stranded siRNA binds to the target mRNA 
sequence, which induces RISC to degrade the mRNA of interest, thereby silencing its expression 
and preventing translation (168, 169). 
CRISPR/Cas9 is a recently developed gene editing tool that has a wide range of 




any other conventional gene editing techniques. This system was discovered first in bacteria as 
part of their adaptive immune system against invading pathogens such as viruses. Bacteria use 
CRISPR to recall viral DNA sequences and when the virus repeats its attack, bacteria synthesize 
a segment of RNA that binds to the viral DNA which is then recognized by Cas9 or a similar 
enzyme and cuts the viral DNA, thereby disabling the virus and protecting the host cells. This 
mechanism can be replicated both in vitro and in vivo by designing a short sequence of RNA (20 
bases) called guided RNA (gRNA) that is complementary to the targeted DNA sequence, which 
allows the associated Cas9 enzyme to cut the double strand DNA at the specific location. This 
technique can be used to eliminate or modify genes of interest (170-172).  
CRISPR/Cas9 was used to generate osteocytic cell line Ocy454 lacking endogenous Gs. 
In addition, lentiviral particles carrying shRNAs were used to knockdown genes of interest as a 






HYPOTHESIS AND AIMS 
We hypothesize that osteocytes regulate proliferation and differentiation of myeloid cells through 
secreted factors in a Gsα-dependent manner.      
 
Aim 1 
Determine the effects of osteocyte-derived secreted factors on myelopoiesis in vitro. 
 
Aim 2 
Determine the effects of osteocyte-derived secreted factors on macrophages and 
osteoclastogenesis. 
a) Effects of osteocyte secreted factors on macrophages.  
b) Effects of osteocyte secreted factors on osteoclasts.  
 
Aim 3  






MATERIALS AND METHODS 
Ocy 454 cell line 
The Ocy454 cell line was generated from long bones of 4-week-old double transgenic mice 
carrying green fluorescence protein (GFP) under the control of the DMP1 promoter and the 
temperature sensitive SV40 large T antigen (173). Long bones were flushed, digested with 
collagenase and EDTA, and crushed into small pieces to obtain osteocytes. Cells were allowed to 
grow in collagen plates at the permissive temperature (33ºC) until confluent (2-3 days) then were 
switched to the semi-permissive temperature (37ºC) for further differentiation (up to 10-12 days). 
Cells were then subjected to cell sorting to isolate the cells expressing high levels of DMP1-GFP 
(42). Cells were routinely maintained in non-collagen-coated flasks (Corning Biocoat) in α-MEM 
containing 10% heat-inactivated Fetal Bovine Serum (FBS) (Gibco) and 1% antibiotic-antimycotic 
(AA) (Gibco); medium was changed twice a week. For all experiments, cells were plated at 1 x 
105 cells/ml and allowed to proliferate at 33ºC for 2-3 days and differentiate at 37ºC for the 
subsequent time specified in each experiment. 
 
CRISPR/Cas 9 gene editing in Ocy454 cells 
Several gRNAs were generated to target exon 1 and 2 of the Gs. gRNA (forward sequence: 5’-
CCT CGG CAA CAG TAA GAC C-3’; reverse sequence: 5’-GAC CGA GGA CCA GCG CAA 
CG-3’) was subcloned into pSpCas9(BB)-2A-GFP (PX458; a gift from Feng Zhang) (Addgene 
plasmid # 48138) (174), which co-express sgRNA, Cas9, and eGFP and was used to target Gsα in 
Ocy454 (175). The empty vector was used to generate control cells. Ocy454 cells were plated at 1 
x 105 cells/ml in 6-well plates and were incubated at 33ºC. After 48 hours in culture, cells were 




mixing 3 μl of FuGENE®, 1 μg of plasmid, and 100 μl of serum-free medium per well of a 6-well 
plate, applied to the cells followed by incubation at 37ºC for 48 hours. Next, eGFPhi cells were 
sorted by FACS and single cells were plated in 96-well plates. Medium was changed twice per 
week during cell expansion. Cells were routinely maintained at 33ºC in non-collagen coated T-75 
flasks. To account for clonal variability, three different knockout subclones (Ocy454 Gsα KO-1, 
KO-2 and KO-3) and three different control subclones (Ocy454 Gsα Control-1, Control-2 and 
Control-3) (176) were isolated.  
  
Preparation of Ocy454 Gsα Control and KO conditioned media 
Ocy454-GsαKO and Ocy454-GsαCtrl clones were plated at 1 x 105 cells/ml in 6-well plates and were 
cultured in complete medium (alpha-MEM, 10% FBS, and 1% AA). Cells were allowed to 
proliferate at 33ºC (permissive temperature) for three days prior to medium change and were then 
transferred to 37ºC (non-permissive temperature) for six additional days to allow differentiation, 
with a media change on day four. On day six, medium was changed to low (alpha MEM, 0.1% 
FBS) or regular (alpha MEM, 10% FBS) serum-containing medium. Conditioned medium (CM) 
was collected 24 hours later, aliquoted, and stored at -20ºC until use. 
 
PTH responsiveness 
For PTH treatment experiments, Ocy454-GsαKO and Ocy454-GsαCtrl cells were plated at 1 x 105 
cells/ml and allowed to reach confluence at 33°C for three days. Cells were then cultivated at 37°C 
for 7 and 14 days. Cells were treated with 10 nM human parathyroid hormone (hPTH) (1-34) or 





Protein extraction and immunoblotting  
Whole cell lysates from cell culture were prepared using lysis buffer containing 50 mM Tris-base, 
1 mM EDTA, 1.5 mM MgCl2, 150 mM NaCl, 1% Triton X-100, and 10% glycerol supplemented 
with protease and phosphatase inhibitors (Sigma, #P5726-1ML and P0044-1ML, respectively). 
Protein concentration was determined using the Bradford protein assay (Protein Assay Dye 
Reagent, Bio-Rad). BSA (New England Biolabs) was used to generate a standard curve. 
Approximately 15-20 μg of protein were separated on a 10% polyacrylamide gel (Fisher Scientific) 
and transferred to a PVDF membrane (Bio-Rad). The membranes were blocked with blocking 
buffer (TBST) supplemented with 5% BSA (Sigma) for one hour and incubated overnight at 4°C 
with anti-Gsα antibody (diluted 1:2000) (Millipore, cat# 06-237). Following overnight incubation, 
membranes were washed three times with TBST, and hybridized with HRP-conjugated secondary 
antibody (anti-rabbit IgG, diluted 1:2000, Cell Signaling, #7074) in blocking buffer for one hour 
at room temperature. The membranes were developed using enhanced chemiluminescence or 
SuperSignal™ West Femto (Thermo Fisher Scientific) and the signals were detected using a 
charge-coupled device (CCD) camera on G: Box (Syngene). 
 
Colony formation in Methylcellulose 
Bone marrow cells were obtained from the long bone of 6-8 weeks old mice (C57BL/6NCrl, 
Charles River Laboratories). Bone marrow was flushed using phosphate-buffered saline (PBS)-
2% FBS, followed by centrifugation at 1,200 rpm for 10 minutes at 4ºC. The medium was 
removed, and the cells were resuspended in 5 ml of alpha-MEM, 10% FBS, and 1% AA. Cells (2 
x 104 cells) were cultured in MethoCult containing CM from Ocy454-GsαKO and Ocy454-GsαCtrl 




for the growth of myeloid cells: MethoCult M3534 and M3231. MethoCult M3534 contains 
growth factors and cytokines (FBS, BSA, insulin, transferrin, 2-mercaptoethanol, IL-3, and IL-6) 
that support the growth of myeloid cells whereas MethoCult M3231 lacks growth factors and 
cytokines. CM of Ocy454-GsαKO and Ocy454-GsαCtrl CM or alpha MEM with 0.1% FBS (no 
treatment) (600 µl) were mixed with either M3534 or M3231(3 ml). These mixtures were placed 
in 35mm culture dishes with a 2 mm grid (174926, Nalge Nunc), followed by incubation at 37ºC. 
After seven days in culture, colonies were counted using a microscope (EVOS Cell Imaging 
System, Thermo Fisher). Numbers of colonies comprised of more than 25 cells were scored. Each 
experiment was repeated at least three times. 
 
Bone marrow mononuclear cell isolation and differentiation   
Bone marrow cells were obtained from the long bone of 6-8 weeks old C57BL/6N female mice 
that were cultured for 24-48 hours. Non-adherent cells were collected and separated by Ficoll 
Paque PLUS (General Electric Healthcare) to isolate the bone marrow mononuclear cell (BMNC) 
population. BMNCs (2 x 104 cells/well) were plated in a 96-well plate, followed by treatment with 
50 ng/ml of M-CSF (Shenandoah, Cat# 200-08) in complete medium (10% FBS) as a control or 
in CM from Ocy454-GsαKO and Ocy454-GsαCtrl (50% v/v). After 3 days in culture, 50 ng/ml of 
RANKL (Shenandoah, Cat# 200-04l) was added, followed by incubation for an additional 2, 3, 5, 
and 7 days. TRAP staining was performed, and TRAP activity was determined following 2, 3, 5, 
and 7 days of RANKL treatment. Cells with 3 nuclei or more were scored as one osteoclast. In 
addition to M-CSF and RANKL treatments, BMNCs were treated with recombinant mouse 
granulin (1000 ng/ml) (R&D, Cat# 2557-PG-050) or recombinant mouse neuropilin-1 (1000 




RAW 264.7 mouse monocyte/macrophage cell line 
In some experiments, 5 x 103 RAW cells per well were plated in 96-well plates. Cells were treated 
with 50 ng/ml RANKL (Shenandoah, Cat# 200-04l) in complete media (10% FBS) as a control or 
in Ocy454-GsαKO and Ocy454-GsαCtrl CM (50% v/v). Following three days of RANKL treatment, 
cells were retreated again with RANKL in complete medium with or without CM. After five days 
in culture, osteoclasts were identified by TRAP staining and TRAP activities were assessed. 
 
Quantitative real time PCR 
Ocy454-GsαKO and Ocy454-GsαCtrl cells were plated at 1 x 105 cells per ml in 6-well plates and 
cultured in complete medium for 3 days at 33ºC and for 7-14 days at 37ºC. RNA was isolated after 
7 or 14 days of incubation at 37ºC. For BMNC proliferation, cells were plated at 1 x 105 in 12-well 
plates and treated with M-CSF (50 ng/ml) and Ocy454-GsαKO and Ocy454-GsαCtrl CM (50% v/v). 
RNA was extracted after 6 days in culture. For osteoclast differentiation experiments, BMNCs 
were plated at 1 x 105 in 12-well plates and then treated with M-CSF and Ocy454-GsαKO and 
Ocy454-GsαCtrl CM for three days. Next, BMNCs were treated with 50 ng/ml RANKL for an 
additional three and five days in addition to the initial treatment with M-CSF and CM. RNA was 
extracted following three and five days of RANKL treatment. In all experiments in this study, 
RNA was isolated using the RNAeasy kit according to the manufacturer’s recommendations 
(RNAeasy, Qiagen). RNA was quantified by UV absorbance (NanoDrop, Thermo Fisher). cDNA 
was synthesized from 0.5-1 g of total RNA using qScripttm cDNA Super Mix (Quanta, 
Biosciences), followed by SYBR Green (Power SYBR, Thermo Fisher Scientific) semi-




samples were calculated using the comparative cycle threshold (CT) method 2 (-∆∆CT). β-actin 
was used as reference. Experiments were run in triplicate unless otherwise indicated.  
 
Genes Forward sequences Reverse sequences 


























CyclinD 5’-GCGTACCCTGACACCAATCTC-3’ 5’-CTCCTCTTCGCACTTCTGCTC-3’ 


























































Mif 5’-GCCAGAGGGGTTTCTGTCG-3’ 5’-GTTCGTGCCGCTAAAAGTCA-3’ 






Mmp2 5’-CAAGTTCCCCGGCGATGTC-3’ 5’-TTCTGGTCAAGGTCACCTGTC-3’ 







Tgf- 5’-CGTCACTGGAGTTGTACGGC-3’ 5’-TGGGGCTGATCCCGTTGATT-3’ 
Table 1. RT-qPCR primer sequences used in this study. 
 
Cell viability and proliferation assays 
For all experiments, 2 x 104 BMNCs per well were plated in 96-well plates. BMNCs were treated 
either with Ocy454-GsαKO CM, Ocy454-GsαCtrl CM or complete medium (as an experimental 






Presto Blue for cell viability 
After seven days in culture, culture medium was replaced with PrestoBlue stain (100 μl per well; 
Thermo Fisher), followed by incubation at 37ºC for two hours prior to spectrophotometric analysis 
(OD at 540 nm and 590 nm as reference). 
 
CYQUANT 
After 6, 24, 48, 72, 96, and 168 hours (7 days) in culture, cells were frozen at -80ºC. Reagents 
were prepared according to the CYQUANT Cell Proliferation Assay protocol (Invitrogen). Plates 
were thawed at room temperature and 200 µL of fluorescent reagent was added to each well, 
followed by incubation for 15 minutes at room temperature with light protection. From each well, 
150 µL were transferred to a black 96-well plate (Corning). Fluorescence was measured with a 
microplate reader at 490 nm excitation and 533 nm emission. Bacterial DNA was used to generate 
a standard curve to determine the DNA concentration (ng/ml) in each sample.  
 
Flow cytometry 
BMNCs (1 x 105 per well) were cultured in 12-well plates and treated with Ocy454-GsαKO CM, 
Ocy454-GsαCtrl CM or complete media (as an experimental control). After four days in culture, 
BMNCs were stained for 20 minutes with fluorescence-conjugated antibodies against CD11b, 
F4/80, and Gr1 (1:200 dilution) (eBioscience). After staining, cells were washed with 2% FBS-






Culture media were aspirated from the 96-well plates and cells were washed with PBS (Gibco). 
Cells were fixed in 10% formalin (10-15 minutes, at room temperature), then washed once with 
PBS. Acetone and methanol (50:50) were used to fix the cells. TRAP staining solution contained 
(1 M sodium acetate, 1 M of sodium tartrate, naphthol AS-MX phosphate (Sigma, Aldrich), red-
violet LB salt (Sigma, Aldrich) and distilled water (pH 5) was added, followed by incubation at 
37ºC for 20-30 minutes. Plates were washed with water and allowed to dry. Osteoclasts were 
counted under the microscope (EVOS Cell Imaging System, Thermo Fisher). A cell with three or 
more nuclei was scored as one osteoclast. Occupancy of surface area by osteoclasts was calculated 
using Image J software and manual tracing of each osteoclast in each well. 
 
TRAP activity  
Cell culture supernatant (30 l) was placed in a 96-well plate. TRAP solution (same as above) was 
added to each well (170 l/well). The plate was incubated at 37ºC for 1.5-2 hours in dark. A plate 
microreader was used to read the OD values at 540 nm. TRAP solution alone was used as a 
reference and subtracted from each sample reading.  
 
Resorption pit assay  
BMNCs (2 x 104 cells per well) were plated in a 96-well plate (Osteo Assay Surface, Corning). 
BMNCs were treated with 50 ng/ml M-CSF in complete medium (10% FBS) as a control or with 
Ocy454-GsαKO or Ocy454-GsαCtrl CM (50% v/v). After three days in culture, BMNCs were treated 
with 50 ng/ml RANKL in addition to 50 ng/ml M-CSF. Treatment was repeated every three days. 




bleach (10 minutes at room temperature). The plate was then washed twice with 150 µl per well 
of distilled water and was air-dried for one hour at room temperature. Pits were visualized with a 
microscope (EVOS Cell Imaging System, Thermo Fisher) and analyzed using Image J software. 
 
F-actin ring staining  
After five days of RANKL treatment, culture medium was aspirated, followed by washing with 
PBS. Cells were fixed with 10% formalin, washed twice with PBS, permeabilized with 0.5% 
Triton X-100 (diluted in PBS) for five minutes at room temperature, and then incubated with 0.5 
µg/ml rhodamine phalloidin (Invitrogen) for 30 minutes in dark. DAPI was used to stain nuclei. 
Cells were washed with PBS and examined under fluorescence microscopy (BZ-X700, 
KEYENCE). 
 
Apoptosis assay for osteoclasts 
Following five days of RANKL treatment, 100 l of Caspase Glo® 3/7 reagent (Apo-Tox Glo™, 
Promega) was added to each well. The plate was rocked on a shaker at 500 rpm for 30 seconds 
then incubated at room temperature for 30 minutes. A microplate reader was used to measure the 
luminescence generated by the caspase activity. 
 
Osteocytes enrich bone explants (OEBE) preparation 
OEBE were generated from femurs and tibia of 6-weeks old DMP1-Cre Gsαf/f mice or control 
Gsαf/f mice as described previously (72). Briefly, after removing the epiphyses and flushing out 
the bone marrow (BM), the explants were sequentially digested three times using collagenase and 




osteoblasts and BM cells. Twenty l of complete medium was used for every 10 mg of OEBE. 
OEBEs were plated in 12-well plates and cultured at 37ºC in 5% CO2 for 24 hours prior to changing 
the medium, followed by five days of additional culture. CM was then collected and stored at -
20ºC. CM from OEBEs were used to treat BMNCs with M-CSF and RANKL as described above 
in ‘Osteoclast differentiation’ section. RNA was isolated from OEBE with Trizol (Invitrogen) 
using a tissue homogenizer (TissueLyser, Qiagen) and the Purelink RNA mini kit (Invitrogen, 
Thermo Fisher) according to the manufacturers’ recommendations.  
 
Lentivirus production 
Validated shRNAs were purchased from Sigma-Aldrich. HEK293T cells were plated at 2.2 x 
105 cells/ml in 6-well plates in high-glucose DMEM (Gibco) and 10% FBS without antibiotics. 
Cells were transfected the next day at approximately 80% confluency. In each well, 100 µl of 
serum-free DMEM, 500 ng of pLKO1 puro plasmid containing the gene of interest, 500 ng of 
psPAX2 (a gift from Dr. Trono, Addgene #12260) and 50 ng of pMD2.G (a gift from Dr. Trono, 
Addgene #12259) were transfected using 3 l of FuGENE® HD transfection reagent (Promega). 
Twenty-four hours after the transfection, media were replaced with DMEM + 10% FBS with 
antibiotic-antimycotic. After 48 hours, medium was collected from each well, spun down at 1,000 
rpm, 4°C for 10 minutes, and virus supernatant was collected, aliquoted, and stored at -80°C. 
 
Lentivirus infection 
Ocy454-GsαKO and Ocy454-GsαCtrl cells were plated at 1 x 105 cells/mL in 12-well plates 24 hours 
before infection. Cells were infected at 80% confluency with 100 l of lentivirus in the presence 




puromycin was added to the medium. Medium (containing puromycin) were replaced every three 
days thereafter. At day 10 in culture, the cells were trypsinized and transferred to T-25 flask. 
Subsequently, CM were collected as described above.  
 
Mass spectrometric analysis 
Phenol-free medium (Gibco) without FBS was used to prepare CM from both Ocy454-GsαKO and 
Ocy454-GsαCtrl cells. Amicon columns (30K; Millipore) were washed with 0.1 N NaOH and then 
with Milli-Q water. Amicon columns were used to separate proteins in CM into > 30K and < 30K 
fractions. The < 30K fraction was placed in a C18 cartridge and sequentially eluted with 30-60% 
acetonitrile and 1% formic acid. Flow samples through the C18 cartridge were collected in 1.5 ml 
microcentrifuge tubes and placed in a speed vacuum for dryness; the samples were then suspended 
in 30 L of 0.1% RapiGest in 100mM tri-ethyl- ammonium bicarbonate (TEAB). A solution of 
ethanol, acetone, and 0.1% acetic acid was chilled at -20C for one hour then 1 ml of this solution 
was added to > 30K fractions and kept at -20C overnight. The next day, the > 30K fractions were 
centrifuged (20,000 x g at 4C for 10 minutes). Tubes were inverted to decant the solution into 
new tubes without disturbing the pellets. Pellets were allowed to dry for three minutes then 
suspended in 30 L of 0.1% RapiGest in 100mM tri-ethyl- ammonium bicarbonate (TEAB) and 
mixed by vortexing. Both fractions were reduced by dithiothreitol (DTT) and alkylated by 
iodoacetamide and digested overnight with trypsin at 37C, then dried by speed vacuum and 
subjected to proteomic analysis (Matrix Assisted Laser Desorption/ Ionization (MALDI) and 







Data were presented as mean ± SEM. Statistically significant differences between groups and 
treatments were determined by the student t-test or ANOVA using Graph Pad Prism software. P 
values < 0.05 were considered as statistically significant. Each experiment was conducted in 






Characterization of Ocy454 cell line 
The Ocy454 cell line was derived from long bones of double transgenic mice carrying the genes 
for both SV40TAg and DMP1-GFP. GFP positive cells were isolated by FACS as previously 
described (42). Gnas was knocked out using the CRISPR/Cas9 technique. The Ocy454 cell line is 
a heterogeneous population that contains cells with various degrees of maturation, as recently 
reported (42). To account for clonal variability, three different knockout subclones (Ocy454 Gsα 
KO-1, KO-2, and KO-3) and three control subclones (Ocy454 Gsα Control-1, Control-2, and 
Control-3) were generated. Gsα deletion in Ocy454-GsαKO and Ocy454-GsαCtrl subclones was 
confirmed at both protein and transcript level (Figure 5A-5B). 
The Ocy454 cell line displays a dendritic morphology and responds to PTH and mechanical 
loading by regulating expression of SOST, RANKL, and DMP1, similar to more physiological 
osteocytes in vivo. Deletion of Gs in the Ocy454 cell line resulted in a significant increase of 
Dmp1, Phex, Sost expression and decreased expression of Rankl (Figure 5C-F). To examine 
functional inactivation of Gsα, we analyzed responsiveness of the Ocy454 cell line to PTH. The 
Ocy454 cell line responded to PTH by suppressing Sost and Dmp1 expression and by increasing 
Rankl expression as shown previously (42). Ocy454-GsαCtrl and Ocy454-GsαKO were treated for 4 
hours with either human PTH (1-34) (10 nM) or forskolin (10 M), which is an activator of 
adenylate cyclase that results in increased levels of cAMP. As expected, Ocy454-GsαCtrl clones 
responded to PTH with a significant suppression of Dmp1 and Sost expression and increased Rankl 
expression. A similar effect was induced by forskolin treatment (Figure 5F). In the absence of Gs 
expression, there was no response to PTH treatment, which confirmed the successful deletion of 




cells, which both showed significant reduction in Dmp1 and Sost expression and a significant 
increase in Rankl expression (Figure 5H).  
Next, we evaluated proliferation rate of Ocy454-GsαCtrl and Ocy454-GsαKO cells to assess 
whether the different amount of secreted proteins was dependent on the number of cells. There 
were no significant differences in DNA concentration between Ocy454-GsαCtrl and Ocy454-GsαKO 
cells, demonstrating that silencing of Gsα in Ocy454 does not affect cell proliferation (Figure 5I). 
 
5-A) Gs mRNA expression. 
  
 
5-B) Gs protein level.  
(nonspecific bands are results from alternative splicing of GNAS include extra-large Gs (Xls) 






































































































































































































































































































Figure 1: Characterization of Ocy 454 cell line


































































































































































































































































































Figure 1: Characterization of Ocy 454 cell line

















































































































































































































































































































































































































































































































Figure 5: Characterization of Ocy454 cell lines.  
A) mRNA expression of Gsα. B) Gs protein level. C) mRNA expression of Dmp1. D) mRNA 
expression of Sost. E) mRNA expression of Phex. F) mRNA expression of Rankl. G) Ocy454 
GsαCtrl responses to PTH and Forskolin treatments. H) Ocy454 GsαKO responses to PTH and 
Forskolin treatments. I) Proliferation of Ocy454 GsαCtrl and Ocy454 GsαKO cells. *p < 0.05 (t-Test 
/one-way ANOVA). Error bars represent mean +/- SEM (n=3). 
  















































































































































































































Osteocytes secrete factors capable of inducing myeloid cell proliferation in vitro 
Mice lacking expression of Gsα in osteocytes have increased levels of myeloid cells in bone 
marrow, spleen, and peripheral blood. Furthermore, ex vivo studies using conditioned medium 
(CM) from OEBE demonstrated that osteocytes secrete factor(s) that support myeloid 
proliferation. CM from OEBE prepared from DMP1-GsαCtrl and DMP1-GsαKO animals were used 
to assess the effects of osteocytes on myeloid cells (72). To further study the molecular 
mechanisms of osteocyte-mediated myeloid cell proliferation, we used an in vitro model in which 
CM from Ocy454-GsαCtrl and Ocy454-GsαKO cells were used to induce myeloid proliferation.  
Using supportive methylcellulose media (M3534), there was a significant increase in the 
number of myeloid colonies after treatment with Ocy454-GsαCtrl CM. The number of myeloid 
colonies was further increased after treatment with Ocy454-GsαKO CM (Figure 6A). CM from 
additional Ocy454-GsαCtrl and Ocy454-GsαKO clones showed similar effects (Figure 6B). We then 
examined the effect of CM on myeloid cell proliferation using non-supportive medium to eliminate 
the effect of growth factors. Consistent with previous results, there was a significant increase in 
the number of myeloid cells when the cells were cultured in non-supportive methylcellulose 
medium (M3231) and treated with CM from Ocy454-GsαCtrl as compared to medium alone. The 
number of colonies was further increased by treatment with CM from Ocy454-GsαKO cells (Figures 
6C and 6D). As shown in Figure 6E, there was a significant increase of DNA synthesis in myeloid 
cells treated with CM from Ocy454-GsαKO cells as compared to Ocy454-GsαCtrl cells or medium 
alone, demonstrating that osteocytes secrete factor(s) capable of promoting myeloid cell 





6-A) Quantification of myeloid cells using myeloid supporting medium. B) Treatment of 
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Figure 2: Osteocytes secrete factor capable of inducing myeloid cells proliferation
E



















































































































6-D) Quantification of myeloid colonies after CM treatment in non-supporting medium. 
 
 
6-E) Myeloid cell proliferation in response to CM treatment as assessed by DNA content. 
 
__________________________________________________________________ 
Figure 6: Osteocytes support myeloid cell proliferation through secreted factors.  
A) Quantification of myeloid colonies grown in myeloid-supporting medium. B) Treatment with 
CM from different control and KO clones using supporting myeloid medium. C) Microscopic 
images of myeloid cells after CM treatment in non-supporting medium. D) Quantification of 
myeloid colonies after CM treatment in non-supporting medium. E) Proliferation of myeloid cells 
after CM treatment compared to non-treatment control.  *p < 0.05 (One-way ANOVA). Error bars 
represent mean +/- SEM (n=3).  
  



























































Osteocytes promote proliferation of bone marrow mononuclear cells (BMNCs) and 
macrophages  
As reported previously, mice lacking Gs in osteocytes have increased numbers of myeloid cells 
and marked osteopenia. (72). Progenitor cells in the myeloid lineage give rise to monocytes and 
macrophages, eventually differentiate into osteoclasts in the bone. We investigated the effects of 
osteocyte-secreted factors on BMNCs proliferation. BMNCs were isolated from bone marrow of 
tibias and femurs of wild-type female mice using a Ficoll gradient. BMNCs were treated with CM 
from Ocy454 GsαCtrl and Ocy454 GsαKO or with medium alone. As shown in Figure 7A, CM from 
Ocy454 GsαCtrl and Ocy454 GsαKO cells significantly increased the number of BMNCs. A viability 
assay showed a significant increase in the number of viable cells after the treatment with Ocy454 
GsαCtrl or Ocy454 GsαKO CM as compared to medium control (Figure 7B).  
As shown in Figure 7C, there was a significant increase of DNA synthesis in BMNCs 
treated with CM from Ocy454 GsαCtrl and Ocy454 GsαKO as compared to the medium alone. Time-
course analysis showed that BMNCs proliferation significantly increased after 24 hours of 
treatment with CM, which further increased over time as compared to the non-treatment control 
(Figure 7D). Flow cytometric analysis using antibodies to different cell populations in BMNCs 
demonstrated a significant increase in the number of CD11b+F4/80high cells (macrophages) after 
treatment with CM as compared to no treatment control. CD11b+/F4/80Low cells (monocytes) and 
CD11b+/Gr1+ cells (granulocytes) did not differ significantly from no treatment controls, 
suggesting that osteocytes secrete factor(s) that promote specifically macrophage proliferation 
(Figure 7E). Next, we isolated OEBE from mice lacking Gsα in osteocytes (DMP1-Cre; Gsαfl/fl or 
GsαKO) or littermate controls (Gsαfl/fl or GsαCtrl) (72). CM from OEBE-GsαCtrl and OEBE-GsαKO 




OEBE was used as a control to rule out any effect of the bone matrix. Proliferation assay shows a 
significant increase in the number of BMNCs after treatment with CM from OEBE-GsαCtrl and 
OEBE-GsαKO. Interestingly, CM from non-viable OEBE was also able to support BMNCs 
proliferation as compared to no treatment control (Figure 7F). These results demonstrate that 
osteocytes secrete factors that induce proliferation of BMNCs, in particular macrophage, in a Gs-
independent manner.  
 
7-A) Microscopic images of BMNCs after Ocy454 CM treatment. 
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Figure 3: Osteocytes secrete factor inducing bone marrow macrophage proliferation
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7-C) Proliferation of BMNCs after Ocy454 CM treatment in vitro. 7-D) Time course of 
BMNC proliferation after Ocy454 CM treatment. 
 
 
7-E) Flow cytometry of BMNCs after the treatment with CM or complete media  
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7-F) Proliferation assay of BMNCs after OEBE CM treatment (ex vivo).  
 
______________________________________________________________________________ 
Figure 7: Osteocytes promote BMNC proliferation via secreted factor(s). 
A) Microscopic images of BMNCs after Ocy454 CM treatment. B) Viability assay using Presto 
blue staining to assess BMNC viability after Ocy454 CM treatment. C) Cyquant proliferation assay 
of BMNCs after Ocy454 CM treatment. D) Time course of BMNC proliferation stimulated with 
Ocy454 (GsαKO and control) CM treatment. E) Flow cytometry of BMNCs after the treatment 
with CM or complete media. F) Proliferation of BMNCs after OEBE CM treatment (ex vivo). *p 





Osteocytes suppress osteoclast differentiation via secreted factor(s)  
DMP1-Gs  KO mice display myelopoiesis and marked osteopenia. Osteoclasts are terminally 
differentiated macrophages that are derived from the myeloid lineage. We hypothesized that 
osteopenia could be caused at least in part by increased osteoclast activity and that osteocyte-
secreted factors may affect osteoclasts through a Gs-dependent mechanism. BMNCs were treated 
with M-CSF (50 ng/ml) and CM from Ocy454 GsαCtrl or Ocy454 GsαKO cells for 5, 7, 8, and 10 
days. RANKL (50 ng/ml) was added on day 3 of cell culture and fresh cytokines (M-CSF and 
RANKL) and CM were added at each medium change. Time-course experiments demonstrated 
that, at day 2 in culture with RANKL, there was no significant effect by CM, either from Ocy454 
GsαCtrl cells or Ocy454-GsαKO cells, in osteoclast number, Trap activity, percentage of surface area 
covered by osteoclasts, and average cell area. However, at day 3 of RANKL treatment, CM from 
both Ocy454 GsαCtrl and Ocy454 GsαKO cells significantly suppressed osteoclast number, Trap 
activity, the surface area covered by osteoclasts, and average cell area, compared to no CM 
treatment. At day 5 of RANKL treatment, all of osteoclast number, Trap activity, the surface area 
covered by osteoclasts, and average cell area were significantly reduced in the Ocy454-GsαKO CM 
group compared to Ocy454-GsαCtrl CM control. At day 7 day of RANKL treatment, most of the 
osteoclasts underwent apoptosis and we could not detect any differences among three conditions 
in all parameters described above (Figure 8A-E).  
To further analyze the effects of CM treatment on osteoclastogenesis, mRNA expression 
of osteoclast-specific genes was analyzed at day 3 and 5 of RANKL treatment. At day 3, expression 
of Trap, Ctsk, Mmp9, Dc-stamp, and Atp6v0d2 mRNA was significantly decreased in cells treated 
with CM as compared to medium alone (Figure 8F). At day 5, expression of Trap, Ctsk, Mmp9, 




control, whereas expression of all the 6 genes remained significantly lower than that of no-CM 
control (Figure 8G). Osteoclast apoptosis was significantly increased with Ocy454 GsαCtrl CM and 
Ocy454 GsαKO CM treatments as compared to no-CM control, suggesting that osteocytes secrete 
factor(s) that inhibit osteoclast differentiation and promote osteoclast apoptosis (Figure 8H).  
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8-B) Number of osteoclast. C) Trap activity. D) Percentages of surface area covered by 
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8-F) mRNA expression of osteoclast markers after 3 days in RANKL treatment. 
 
 
8-G) mRNA expression of osteoclast markers after 5 days in RANKL treatment. 
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Figure 8: Osteocytes suppress osteoclast differentiation via secreted factor(s). 
A) Time course of osteoclast differentiation in CM at 2, 3, 5, and 7 days of RANKL treatment. B) 
Osteoclast number. C) Trap activity. D) Percentages of surface area covered by osteoclasts. E) 
Average cells area. F) mRNA expression of osteoclast-specific genes Trap, Ctsk, Mmp9, Dc-stamp 
and Atp6v0d2 after three days of RANKL treatment. G) mRNA expression of osteoclast-specific 
genes after five days of RANKL treatment. H) Apoptosis of osteoclasts.  *p < 0.05 (One-way 
ANOVA). Error bars represent mean +/- SEM (n=3).    
 
Osteocytes inhibit osteoclast function 
Based on our observation that osteocyte CM inhibited osteoclast differentiation, we hypothesized 
that osteocytes also affect osteoclast function. We examined several functional parameters of 
osteoclasts after treatment with Ocy454 GsαCtrl CM or Ocy454 GsαKO CM. BMNCs were cultured 
in osteo-assay plates and treated with M-CSF and RANKL in Ocy454 GsαCtrl CM, Ocy454 GsαKO 
CM, or control medium. After 10 days in culture, there was a significant suppression of osteoclast 
activity in cells treated with CM from Ocy454 GsαCtrl and Ocy454 GsαKO as compared to the 
medium control (Figure 9A-C). The percentage of the resorbed area was not significantly different 




resorbed area was significantly higher in cells treated with Ocy454 GsαCtrl CM as compared to 
Ocy454 GsαKO CM (Figure 9C). 
Formation of F-actin rings in osteoclasts is essential for proper function. F-actin staining 
was performed to evaluate the integrity of the osteoclast rings. There was a significant decrease in 
the number of osteoclasts with an intact F-actin ring when treated with CM from Ocy454 GsαCtrl 
and the number was further reduced by the treatment with CM from Ocy454 GsαKO cells (Figure 
9D and 9E).  
 
9-A) Microscopic images of resorption area produced by osteoclasts. B) Percentage of 




Figure 5: Osteocytes inhibit osteoclast function
A
No CM (Control) Gsα control CM Gsα KO CM
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Figure 9: Osteocytes inhibit osteoclast functions via secreted factors.  
A) Microscopic images of resorption area induced by osteoclasts. B) Percentages of resorbed area. 
C) Numbers of resorbed area. D) Rhodamine staining of F-actin rings in osteoclasts. E) 
Quantification of osteoclasts with an intact actin ring. *p < 0.05 (One-way ANOVA). Error bars 
represent mean +/- SEM (n=3). 
 
Osteocytes suppress osteoclast differentiation (ex vivo) 
To validate our in vitro findings in ex vivo model, we isolated OEBES from DMP1-Cre; Gsαfl/fl 
and littermate control (Gsαfl/fl or GsαCtrl) (72). CM from OEBE-GsαCtrl and OEBE-GsαKO were 
prepared and used to treat BMNCs isolated from the bone marrow of wild-type mice and grown 
in the presence of both M-CSF and RANKL as described above.  
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After 3 days of RANKL treatment, there was a significant decrease in osteoclast 
differentiation that resulted in significantly lower numbers of osteoclasts, Trap activity, and 
surface area covered by osteoclasts in cells treated with CM from OEBE-GsαCtrl and OEBE-GsαKO 
as compared to medium alone (Figure 10 A-D). Furthermore, after 5 days of RANKL treatment, 
there was a significant difference in the number of multinucleated osteoclasts, Trap activity, and 
percentage of surface area covered by osteoclasts between cells treated with CM from GsαKO as 
compared to GsαCtrl OEBEs. All of these parameters were also significantly lower than medium 
alone, suggesting that osteocytes within OEBEs secrete factor(s) that suppress osteoclast 
differentiation and these factors are Gsα-dependent. (Figure 10 E and F).  
 
10-A) TRAP staining of osteoclasts after OEBE CM treatment for three days in the presence 









Figure 5: OEBE secrete factor inhibit osteoclast differentiation
OEBE Gsα control CM OEBE Gsα KO CM
D









































































































Figure 5: OEBE secrete factor inhibit osteoclast differentiation







10-D) Trap staining of osteoclasts after OEBE CM treatment for five days in the presence of 





Figure 10: Osteocytes suppress osteoclast differentiation by producing secreted factor (ex 
vivo).  
(A-D) Three days after RANKL treatment. A) TRAP staining of osteoclasts after OEBE CM 
treatment. B) Trap activity. C) Percentages of surface area covered by osteoclasts. (D-F) Osteoclast 
differentiation after five days of RANKL treatment.  D) Microscopic images of osteoclasts after 
OEBE CM treatment. E) Trap activity. F) Percentages of surface area covered by osteoclasts.     
*p < 0.05 (One-way ANOVA). Error bars represent mean +/- SEM (n=3). 
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Figure 5: OEBE secrete factor inhibit osteoclast differentiation







Osteocytes secrete factor(s) that both induce proliferation and inhibit osteoclastogenic 
differentiation of RAW 264.7 cells, a model of monocytes/macrophages 
Next, we used the monocyte/macrophage-like RAW 264.7 cell line as another model to study the 
effects of osteocyte-secreted proteins on proliferation and osteoclastogenic differentiation. To 
assess proliferation, DNA content was measured in the cells grown in Ocy454 GsαCtrl CM and 
Ocy454 GsαKO CM. Consistent with our earlier studies with BMNCs, Ocy454 GsαKO CM 
significantly induced RAW264.7 cell proliferation as compared to non-treatment control. These 
results further support our conclusion that osteocytes secrete factors capable of promoting 
monocyte/macrophage proliferation (Figure 11A). 
To assess osteoclastogenic differentiation, RAW264.7 cells were plated and treated with 
RANKL in Ocy454 GsαCtrl CM or Ocy454-GsαKO CM. After 5 days, osteoclast differentiation was 
significantly reduced by Ocy454 GsαCtrl CM and even further reduced by Ocy454 GsαKO CM as 
compared to no treatment control as determined by Trap staining, Trap activity, and percentages 
of surface area covered by osteoclasts. Taken together, these data demonstrate that osteocytes 
secrete factor(s) that inhibit osteoclastogenic differentiation of RAW264.7 cells in a Gsα-






Figure 11. Osteocytes secrete factor(s) that induce proliferation of RAW 264.7 cells while 
inhibiting their differentiation into osteoclasts.  
A) Proliferation of RAW264.7 cells. B) Trap staining of RAW264.7 cells after Ocy454 CM 
treatment. C) Trap activity. D) Percentages of surface area covered by osteoclasts. *p < 0.05 (One-
way ANOVA). Error bars represent mean +/- SEM (n=3). 
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Identification of osteocyte-secreted factors 
To identify factors secreted by osteocytes, we performed comparative proteomic analysis of CM 
from Ocy454 GsαKO cells and Ocy454 GsαCtrl cells. Numerous proteins (3,748 proteins in total) 
were detected in the CM of Ocy454-GsαKO cells and Ocy454-GsαCtrl cells. Initial screening 
focused on secreted proteins that were significantly different between Ocy454 GsαKO CM and 
Ocy454 GsαCtrl CM. As a result, secreted proteins known to control myeloid proliferation or 
differentiation were identified (Table 1). Ceruloplasmin (CP) (13.6-fold difference), neuropilin-1 
(NRP-1) (9.3-fold difference), -2-microglobulin (2M) (2.28-fold difference), and granulin 
(GRN) (1.5-fold difference) were significantly increased in Ocy454 GsαKO CM as compared to 
Ocy454 GsαCtrl CM. 
In contrast, Collagen 3α1 (COL3α1) (17.4-fold difference), semaphorin 3D (SEMA3D) 
(8.7-fold difference), semaphorin 3C (SEMA3C) (5.2-fold difference), collagen 1α1 (COL1α1) 
(5.1-fold difference), collagen 1α2 (COL1α2) (4.8-fold difference), semaphorin 3A (SEMA3A) 
(2.9-fold difference), immunoglobulin superfamily member 10 (IGSF-10) (2.8-fold difference), 
matrix metalloproteinase-2 (MMP2) (2.6 -fold difference), elastin microfibril interfacer 2 
(EMILIN2) (1.5-fold difference), and tissue inhibitor matrix metalloproteinase- 2 (TIMP-2) (1.4-
fold difference) were significantly decreased in Ocy454 GsαKO CM as compared to Ocy454 GsαCtrl 
CM (Table 2). However, other proteins known to have a role in myeloid proliferation or osteoclast 
differentiation, such as M-CSF, osteopontin (OPN), macrophage migration inhibitory factor 
(MIF), OPG, and TGF- were identified in the CM although they were not significantly different 
between Ocy454 GsαKO and Ocy454 GsαCtrl CM (Table 2). 
Expression of the genes corresponding to these identified proteins was analyzed in both 




proteomic analysis, mRNA expression of Col3α1, Sema3c, Col1α2, Sema3a, Mmp2, Emilin2, and 
Sema3d was significantly decreased in Ocy454 GsαKO cells as compared to Ocy454 GsαCtrl cells 
(Figure 12B), whereas expression of Nrp1, Grn, and 2m mRNA was significantly increased in 
Ocy454 GsαKO cells as compared to Ocy454 GsαCtrl cells (Figure 12A). However, expression of 
Timp2, Mif, Opn, Igsf10, Col1α1, Mcsf, and Tgf- was not significantly different between the two 
cell types (Figure 12C). Expression of Cp, Nrp1, Grn, Opg, and Sema3c were significantly 
increased in OEBE-GsαKO as compared to OEBE-GsαCtrl (Figure 13A), whereas Mcsf, Mif, Mmp2, 
Igsf10, Opn, Sema3a, Col1α1, Col1α2, Col3α1, Timp2, Emilin2, and Tgf- was not significantly 







Table 2. Secreted proteins identified in Ocy454 GsαKO CM and Ocy454 GsαCtrl CM.  
CP, NRP-1, 2M and GRN were significantly increased in Ocy454 GsαKO CM compared to 
Ocy454 GsαCtrl CM. COL3α1, SEMA3D, SEMA3C, COL1α1, COL1α2, SEMA3A, IGSF10, 
MMP2, EMILIN2 and TIMP2 were significantly reduced in Ocy454 GsαKO CM compared to 
Ocy454 GsαCtrl CM. M-CSF, OPN, MIF, OPG and TGF- were not significantly different between 
the two groups.  *p < 0.05 (two-way ANOVA) (n=6). Comparative expression of the 
corresponding genes, as determined by qPCR in both Ocy454 and OEBE systems, is also shown. 
 
  



































































Collagen 1α2 (COL1α2) 0.02 -4.8
Semaphorin 3A (SEMA3A) 0.01 -2.9





Elastin microfibril interfacer 2 (EMILIN2)
0.01 -1.5
Tissue inhibitor matrix metalloproteinase-
2 (TIMP2) 
0.02 -1.4




12-(A-C) mRNA expression of identified secreted proteins in Ocy454 GsαCtrl cells and 
Ocy454-GsαKO cells. 
 



























Figure 12. mRNA expression of identified proteins in Ocy454 GsαCtrl cells and Ocy454 GsαKO 
cells. A) mRNA expression of Nrp-1, Grn, 2m and Opg was significantly increased in Ocy454 
GsαKO cells compared to Ocy454 GsαCtrl cells. B) mRNA expression of Col3α1, Sema3c, Col1α2, 
Sema3a, Mmp2, Emillin2, and Sema3d was significantly reduced in Ocy454 GsαKO CM compared 
to Ocy454 GsαCtrl CM. C) Expression of Timp2, Mif, Opn, Igsf10, Col1α1, Mcsf and Tgf-  was 
not significantly different between the two groups. * P< 0.05 (unpaired t-test). Error bars represent 
mean +/- SEM (n=3). 
  
























































































Figure 13. mRNA expression of identified proteins in OEBE GsαCtrl and OEBE GsαKO.  
A) mRNA expression of Cp, Nrp-1, Grn, Opg and Sema3c were significantly increased in OEBE-
GsαKO compared to OEBE-GsαCtrl. B) mRNA expression of Mcsf, Mif, Mmp2, Igsf10, Opn, 
Sema3a, Col1α1, Col1a2, Col3α1, Timp2, Emilin2, Tgf-, 2m, and Sema3d was not significantly 




Bioinformatics analysis of Ocy454-GsαCtrl and Ocy 454-GsαKO cell lysates 
Proteomic analysis of Ocy454 GsαCtrl and Ocy454 GsαKO cell lysates was performed to investigate 
the molecular mechanisms by which deletion of Gs in osteocytes affects macrophage 
proliferation and differentiation, and myelopoiesis. Ingenuity Pathway Analysis (IPA) identified 
145 pathways that were significantly changed in Ocy454 GsαKO cells as compared to Ocy454 
Gsαctrl cells. Using a cut-off of 1.5-log change, 23 significantly affected pathways were identified 
(Table 3). Our data show that the most significantly affected pathway was “protein kinase A 
signaling” with a 3.4-fold decrease in Ocy454 GsαKO cells as compared to Ocy454 Gsαctrl cells. 
Five proteins were found in this category; A-kinase anchoring protein 2 (AKAP2) and filamin A 
(FLNA) were significantly upregulated in Ocy454 GsαKO cells compared to Ocy454 GsαCtrl cells, 
whereas protein kinase cAMP-dependent type II regulatory subunit beta (PRKAR2B), cAMP 












responsive element binding protein 1 (CREB1), and catenin beta 1 (CTNNB1) were significantly 
downregulated in Ocy454 GsαKO cells as compared to Ocy454 GsαCtrl cells. Some of the pathways 
listed in Table 3 may have a role in our model: cAMP-mediated signaling, opioid signaling 
pathway, cardiac β-adrenergic signaling, and purigenic receptor signaling pathway (P2Y).  
Other pathways that were significantly decreased in Ocy454 GsαKO cells as compared to 
Ocy454 GsαCtrl cells include neuroprotective role of THOP1 in Alzheimer’s disease (3.1-fold 
change), integrin-linked kinase (ILK) signaling (2.4-fold change), caveolar-mediated endocytosis 
signaling (2.23-fold change), BMP signaling (2.2-fold change), melanocyte development and 
pigmentation signaling (1.95-fold change), virus entry via endocytic pathways (1.95-fold change), 
prostate cancer signaling (1.95-fold change), neuroinflammation signaling (1.93-fold change), 
Gαs signaling (1.86-fold change), neuropathic pain signaling in dorsal horn neurons (1.82-fold 
change), synaptic long term potentiation (1.77-fold change), corticotropin releasing hormone 
signaling (1.67-fold change), relaxin signaling (1.57-fold change), GNRH signaling (1.54-fold 
change), dopamine-DARPP32 feedback in cAMP signaling (1.54-fold change), ovarian cancer 
signaling (1.69-fold change), and tight junction signaling (1.53-fold change).  
IPA also identified significantly upregulated proteins in Ocy454 GsαKO cells as compared 
to Ocy454 GsαCtrl cells, including HLA-A (2.7-fold change), beta-2-microglobulin (2M) (2.7-
fold change), thymosin, beta 4, X-linked (TMSP4x) (2.4-fold change), clathrin adaptor protein 
(DAB2) (1.93-fold change), proteasome activator subunit 1 (PSME1) (1.75 fold-change), granulin 
(GRN) (1.71-fold change), pleckstrin homology domain containing O2 (PLEKHO2) (1.70-fold 
increase), casein kinase 2 alpha 2 (CSNK2A2) (1.39-fold change), A-kinase anchoring protein 2 
(AKAP2) (1.38-fold change), and FLNA (1.35-fold change). Downregulated proteins in Ocy454 




fold change), molybdenum cofactor synthesis 1 (Mocs1) (1.66-fold change), DExD-box helicase 
50 (DDX50) (1.66-fold change), SEC24 homolog A, COPII coat complex component (SEC24A) 
(1.55-fold change), transmembrane protein 33 (TMEM33) (1.48-fold change), Surfeit 4 (SURF4) 
(1.47-fold change), ribosome binding protein 1 (Rrbp1) (1.46-fold change), CTNNB1 (1.39-fold 
change), PABPC4 (Poly(A) binding protein cytoplasmic 4) (1.38-fold change), Nucleophosmin 1 
(NPM1) (1.38-fold change), DDX21 (DExD-box helicase 21) (1.38-fold change), LYPLA1 
(Lysophospholipase I) (1.32-fold change), SLC25A31 (Solute carrier family 25 member 31) (1.32-
fold change), FILIP1 (Filamin A interacting protein 1) (1.31-fold change), SYNCRIP 
(Synaptotagmin binding cytoplasmic RNA interacting protein) (1.29-fold change), COX5A 
(Cytochrome c oxidase subunit 5A) (1.28-fold change), TXNDC5 (Thioredoxin domain 
containing 5) (1.28-fold change), SRP72 (Signal recognition particle 72) (1.25-fold change), 
KLC1 (kinesin light chain 1) (1.22-fold change), EEF1A1 (eukaryotic translation elongation factor 
1 alpha 1) (1.22-fold change), and SEH1L (SEH1 like nucleoporin) (1.09-fold change) (Table 3). 
Some of the identified proteins were found to be involved in multiple signaling pathways. 
For example, PRKAR2B, CREB1, and CTNNB1 are involved in protein kinase signaling, cAMP-
mediated signaling, Gαs signaling, cardiac β-adrenergic signaling, opioid signaling pathway, 
neuropathic pain signaling in dorsal horn neurons, synaptic long-term potentiation, purigenic 
receptor signaling pathway (P2Y), corticotropin releasing hormone signaling, relaxin signaling, 
GNRH Signaling, dopamine-DARPP32 feedback in cAMP signaling, ovarian cancer signaling, 
and tight junction signaling. Likewise, AKAP2 is involved in protein kinase signaling, cAMP-
mediated signaling, and cardiac β-adrenergic signaling, while FLNA is involved in protein kinase 
signaling, ILK signaling, caveolar-mediated endocytosis signaling, and virus entry via endocytic 






Table 3. Canonical pathways significantly decreased in Ocy454 GsαKO cells compared to 





IPA analysis to identify significantly affected pathways in 
Ocy454 cells
Canonical Pathways -log change P-value Molecules
Protein Kinase A Signaling 3.43 0.0132 AKAP2,PRKAR2B,FLNA,CREB1,CTNNB1
Neuroprotective Role of THOP1 in Alzheimer's Disease 3.14 0.0283 PRKAR2B,HLA-A,CREB1
ILK Signaling 2.43 0.016 FLNA,CREB1,CTNNB1
cAMP-mediated signaling 2.25 0.0138 AKAP2,PRKAR2B,CREB1
Caveolar-mediated Endocytosis Signaling 2.23 0.029 FLNA,HLA-A
BMP signaling pathway 2.2 0.0278 PRKAR2B,CREB1
Opioid Signaling Pathway 2.17 0.0129 PRKAR2B,CREB1,CTNNB1
Melanocyte Development and Pigmentation Signaling 1.95 0.0208 PRKAR2B,CREB1
Virus Entry via Endocytic Pathways 1.95 0.0206 FLNA,HLA-A
Prostate Cancer Signaling 1.95 0.0206 CREB1,CTNNB1
Neuroinflammation Signaling Pathway 1.93 0.0105 HLA-A,CREB1,CTNNB1
Gαs Signaling 1.86 0.0187 PRKAR2B,CREB1
Neuropathic Pain Signaling In Dorsal Horn Neurons 1.82 0.0177 PRKAR2B,CREB1
Synaptic Long Term Potentiation 1.77 0.0167 PRKAR2B,CREB1
Cellular Effects of Sildenafil 1.74 0.0161 PRKAR2B,PABPC4
P2Y Purigenic Receptor Signaling Pathway 1.69 0.0152 PRKAR2B,CREB1
Cardiac β-adrenergic Signaling 1.69 0.0152 AKAP2,PRKAR2B
Corticotropin Releasing Hormone Signaling 1.67 0.0148 PRKAR2B,CREB1
Ovarian Cancer Signaling 1.63 0.0141 PRKAR2B,CTNNB1
Relaxin Signaling 1.57 0.0131 PRKAR2B,CREB1
GNRH Signaling 1.54 0.0126 PRKAR2B,CREB1
Dopamine-DARPP32 Feedback in cAMP Signaling 1.54 0.0125 PRKAR2B,CREB1





Table 4. Identified proteins significantly upregulated and downregulated in Ocy454 GsαKO 
cells as compared to Ocy454 GsαCtrl cells. *p < 0.05 (two-way ANOVA) (n=6). 
 
 
Up-regulated proteins Fold Change P-value
Major histocompatibility complex, class I, A
Beta-2-microglobulin 
Thymosin, beta 4, X-linked 
Clathrin adaptor protein
Proteasome activator subunit 1
Granulin
Pleckstrin homology domain containing O2
Casein kinase 2 alpha 2






















Down-regulated proteins Fold Change P-value
Protein kinase cAMP-dependent type II regulatory subunit beta
cAMP responsive element binding protein 1
Molybdenum cofactor synthesis 1
DExD-box helicase 50
SEC24 homolog A, COPII coat complex component
Transmembrane protein 33
Surfeit 4
Ribosome binding protein 1
Catenin beta 1




Solute carrier family 25 member 31 
Filamin A interacting protein 1
Synaptotagmin binding cytoplasmic RNA interacting protein
Cytochrome c oxidase subunit 5A
Thioredoxin domain containing 5
Signal recognition particle 72
Kinesin light chain 1 
Eukaryotic translation elongation factor 1 alpha 1 

















































The effect of osteocyte-secreted factors on BMNCs and osteoclasts 
We investigated the effects of GRN and 2M on proliferation and differentiation of BMNCs and 
osteoclasts as both factors were significantly increased in Ocy454 GsαKO CM and its cell lysates 
as compared to Ocy454 GsαCtrl counterparts. In addition, we also analyzed the effects of NRP-1 
since this protein was significantly increased in Ocy454 GsαKO CM as compared to Ocy454 GsαCtrl 
CM (Table 1). Lastly, we also included M-CSF and OPG in our analysis as both factors were 
identified as Gsα-independent osteocyte-derived secreted factors. As M-CSF and OPG are known 
to control osteoclast proliferation and differentiation, we explored the possibilities that 
proliferation of BMNCs would be stimulated by osteocyte-derived M-CSF and that inhibition of 
osteoclast differentiation is mediated by osteocytes-derived OPG.  To examine the effects of these 
secreted proteins on BMNCs and osteoclasts, Ocy454 GsαCtrl CM was supplemented with 
recombinant protein or CM was collected from Ocy454 GsαKO cells in which the corresponding 
gene of interest was silenced by shRNA.  
First, BMNCs were treated with recombinant mouse granulin (1000 ng/ml) and Ocy454 
GsαCtrl CM in the presence of M-CSF and RANKL. Our data show that addition of GRN in Ocy454 
GsαCtrl CM led a slight decrease in Trap activity and a significant decrease in surface area of mature 
osteoclasts as compared to Ocy454 GsαCtrl CM treatment alone (Figure 14A). BMNCs grown in 
Ocy454 GsαKO CM in the presence of M-CSF and RANKL were used as a positive control (Figure 
14A, middle). Next, recombinant mouse neuropilin-1 (1000 ng/ml) was added to osteoclast 
cultures in Ocy454 GsαCtrl CM supplemented with M-CSF and RANKL. Our data show that NRP-
1 treated osteoclasts had a significant decrease in the Trap activity (Figure 14B). Additionally, the 




(Figure 14B). These data demonstrate that NRP-1 has Ocy454 GsαKO CM-like inhibitory effects 
on osteoclastogenesis.  
shRNAs targeting Grn, Nrp-1, 2m, Mcsf, and Opg were used to knock-down each of these 
genes in Ocy454 GsαKO cells. We used scrambled shRNA as a control. Suppression of the target 
genes by shRNAs was validated by real-time PCR, which demonstrated a significant decrease in 
Grn (80%), 2m (90%), Nrp-1 (50%), Mcsf (70%), and Opg (85%) expression as compared to 
control cells (Figure 14C). Osteoclasts treated with CM from Grn-knockdown (KD), Nrp-1 KD, 
or Mcsf KD cells showed a significant increase in the surface area covered by osteoclasts, but there 
were no changes in the Trap activity as compared to the cells treated with Ocy454 GsαKO CM 
(Figure 14D-F). CM from 2m KD cells showed no changes in the surface area covered by 
osteoclasts and Trap activity as compared to Ocy454-GsαKO CM treatment (Figure 14G). 
Osteoclasts treated with CM from Opg KD cells showed a significant decrease in the surface area 
covered by osteoclasts and a decrease in the Trap activity as compared to Ocy454-GsαKO CM 
treatment (Figure 14H). 
Lastly, we investigated whether these factors also affect proliferation of BMNCs. Our data 
show that there were no significant changes in BMNCs proliferation when treated with CM from 
Grn, Nrp-1 and 2m KD cells, as compared to CM from shRNA controls (Figure 14I).  In contrast, 
treatment of BMNCs with CM from Mcsf KD cells showed a significant decrease in proliferation 
as compared to shRNA control demonstrating that osteocytes control BMNC proliferation, at least 









B. Osteoclasts were treated with Neuropilin1 (NRP-1) in Ocy454-GsαCtrl CM. 
  
 
Gsαcont CM + vehicle GsαKO CM+ vehicle Gsαcont CM + GRN
Effect of GRN on osteoclast differentiation
*p < 0.05 (one way ANOVA) (n=3) 
























































Gsα cont CM + NRP-1Gsαcont CM + vehicle GsαKO CM+ vehicle
Effect of NRP-1 on osteoclast differentiation
*p < 0.05 (one way ANOVA) (n=3) 






























































C.  mRNA expression of Grn, 2m, Nrp1, Mcsf and Opg in shRNA control and KD cells. 
 
 




shRNA to Knockdown genes of interest in Ocy 454 Gsα KO 
cell






































































Gsα KO Grn KD CMGsα KO CM shRNAGsαcont CM shRNA
*p < 0.05 (one way ANOVA) (n=3) 






























































Gsα KO Nrp1 KD CMGsα KO CM shRNAGsαcont CM shRNA
*p < 0.05 (one way ANOVA) (n=3) 



















































Gsα KO Mcsf KD CMGsα KO CM shRNAGsαcont CM shRNA
*p < 0.05 (one way ANOVA) (n=3) 































































Gsα KO β2m KD CMGsα KO CM shRNAGsαcont CM shRNA
*p < 0.05 (one way ANOVA) (n=3) 


















































Gsα KO Opg KD CMGsα KO CM shRNAGsαcont CM shRNA
*p < 0.05 (one way ANOVA) (n=3) 
























































I. Effects of Grn-, Mcsf-, Nrp1-, and 2m-KD CM on BMNC proliferation.  
 
___________________________________________________________________________ 
Figure 14. Effects of osteocyte-derived secreted factors on proliferation and differentiation 
of BMNCs and osteoclasts. 
Trap staining, Trap activity and the percentages of surface area covered by osteoclasts for A) 
Effects of GRN and Ocy454 GsαCtrl CM on osteoclasts. B) Effects of NRP-1 and Ocy454 GsαCtrl 
CM on osteoclasts. C) mRNA expression of Grn, 2m, Nrp1, Mcsf and Opg in shRNA control and 
KD cells. D) Effects of Grn KD on Osteoclasts differentiation and function. E) Effects of Nrp-1 
KD on Osteoclasts differentiation and function F) Effects of Mcsf KD on Osteoclasts 
differentiation and function G) Effects of 2m KD on Osteoclasts differentiation and function. H) 
Effects of Opg KD on Osteoclasts differentiation and function. I) Proliferation of BMNCs after 
the treatment with Grn KD CM, Mcsf KD CM, Nrp1 KD CM or 2m KD CM.  * P < 0.05 (One-
way ANOVA). Error bars represent mean +/- SEM (n=3). 
  
BMNC Proliferation





Mutations in the GNAS locus, which contains the gene encoding the Gs subunit, are associated 
with many human diseases, including Albright hereditary osteodystrophy (AHO), fibrous 
dysplasia, McCune-Albright syndrome (MAS), progressive osseous heteroplasia (POH), 
pseudohypoparathyroidism, and thyroid and pituitary gland tumors (69). Osteocytes express 
several GPCRs, including PTH1R, the prostaglandin receptors E2-E4, 2 adrenergic receptors, and 
others. It has been shown that Gs signaling in osteocytes controls hematopoiesis both by direct 
cell-to-cell contact and by indirect mechanisms via secretion of soluble factors, as well as through 
the control of intermediate mediators such as osteoblasts and stromal cells.  
We previously reported that DMP1-GsKO mice display severe osteopenia associated 
with increased myelopoiesis in bone marrow, spleen, and peripheral blood. Blood analysis of 
DMP1-GsKO mice demonstrated an increase in neutrophils, monocytes, and platelets compared 
to littermate controls (72). DMP1-GsKO mice also expressed high levels of Sost/sclerostin 
expression and treatment with anti-sclerostin antibodies was able to partially rescue osteopenia but 
not myelopoiesis, suggesting that the abnormal myelopoiesis was independent of sclerostin 
function. In addition, ex vivo studies using CM from OEBE-GsCtrl showed a significant increase 
in myeloid cell proliferation and a further increase with OEBE-GsKO CM treatment. High levels 
of G-CSF were found in the serum of DMP1-GsKO mice as well as in the conditioned medium 
from OEBE, suggesting that osteocytes control myelopoiesis in part by secretion of G-CSF (72).  
Due to the complexity of the physiological settings in vivo and the difficulty of visualizing 
osteocytes in vivo due to their deep location in the mineralized bone matrix, we generated a novel 




CRISPR/Cas9 technique was used to knockout Gs in these cells (176, 177). Functional 
inactivation of Gs in Ocy454 cells was confirmed by their response to PTH and forskolin 
treatment. The use of an in vitro system (Ocy454 cells) allows us to more precisely analyze the 
signaling within osteocytes without confounding effects from other cells such as osteoblasts, 
stromal cells or endothelial cells. Moreover, it is more practical to use gene editing tools to 
manipulate the gene of interest than in vivo mutant animal models, thereby promoting us to better 
understand the molecular mechanisms by which osteocytes regulate myeloid cells.  
The objectives of this study were: 1) to establish an in vitro model of osteocytes lacking 
Gs  (Ocy-454Gs KO cells), 2) to evaluate the role of Gsα-dependent secreted factors on myeloid 
cells, macrophages, and osteoclasts in vitro, and 3) to identify the osteocyte-derived, responsible 
secreted factors. To investigate the effects of osteocyte-secreted factors on myelopoiesis, we first 
investigated the effects of Ocy454 CM on myelopoiesis in vitro. CM were collected from Ocy454 
GsαCtrl cells and Ocy454 GsαKO cells and used to treat bone marrow cells. We found that Gs-
dependent factors released by osteocytes support myeloid cell proliferation. This finding is 
consistent with previous results in both in vivo and ex vivo models (72) and supports the hypothesis 
that osteocytes regulate myeloid cells by providing soluble paracrine factors that are dependent on 
Gsα function.  
Many factors have been reported to increase myeloproliferation, including G-CSF, M-CSF, 
GM-CSF, IL-1, IL-3, IL-6, erythropoietin, thrombopoietin, vascular endothelial growth factor 
(VEGF), and others (178-183). Our previous study showed that G-CSF was elevated in the serum 
of DMP1-Gs KO mice and in CM of their OEBEs, suggesting that G-CSF secreted by osteocytes 
may act as a driver for, in part, myelopoiesis (72). However, we did not find G-CSF as a secreted 




are regulated directly or indirectly by osteocytes. Osteoblasts, monocytes, fibroblasts and 
endothelial cells have been found to secrete G-CSF (184-188), and osteocytes could regulate these 
cells. 
Osteocytes have been shown to work as a master regulator of bone hemostasis by 
controlling both osteoblast and osteoclast functions (7, 12, 35). Osteoclasts are derived from 
monocytes/macrophages, which differentiate from myeloid cells. As we reported previously, 
DMP1-GsKO mice have increased myelopoiesis and severe osteopenia. Initial analysis 
demonstrated that the osteopenia in these animals was mainly due to the suppression of osteoblast 
function (sclerostin-mediated); however, the effect of Gs deletion in osteocytes on osteoclast 
function was not investigated (72). We hypothesize that osteopenia was partially driven by the 
increase of macrophages and osteoclasts (a terminally differentiated form of macrophages). In our 
study, we found that osteocytes supported BMNCs and monocyte/macrophage proliferation both 
in vitro and ex vivo via secreted factors independent of Gs signaling, indicating that osteocytes 
play an important role in the survival and maintenance of BMNCs. Indeed, we have found in our 
study that M-CSF is secreted by osteocytes and plays a critical role in controlling BMNCs 
proliferation.  
Interestingly, heat-inactivated CM derived from OEBE significantly increased BMNCs 
proliferation, suggesting that factors released by the bone matrix also support cell proliferation. 
Indeed, the bone matrix has been shown to be the source of many growth factors, including TGF-
, BMP, OPN, IGF, VEGF, PDGF, Collagen I, and BSP (189-191). The bone matrix also serves 
as a source of minerals including calcium and phosphate which may support cell growth and 




showed an increase of proliferation in the cells grown in Ocy454-GsαKO CM, suggesting that 
monocyte/macrophage proliferation is not fully dependent on M-CSF. 
In our study, BMNCs and RAW 264.7 cells treated with CM from Ocy454 cells or OEBEs 
displayed a significant suppression in osteoclast differentiation and maturation, which were further 
suppressed by CM from Gs KO cells or Gs KO OEBE. The osteoclast functional assays 
indicated no difference in the size of the resorption area between Ocy454 GsαCtrl CM and Ocy454 
GsαKO CM treatment; however, a significant decrease in the number of resorption areas was 
observed with Ocy454 GsαKO CM treatment, suggesting that a decrease in the number of active 
osteoclasts and/or a defect in osteoclast activity must be involved. F-actin ring is needed for proper 
osteoclast function. F-actin ring staining and Trap staining demonstrated that osteocyte-secreted 
factors alter the osteoclast cytoskeleton and inhibits F-actin ring formation, leading to the defect 
in podosomes and in osteoclast activity. These findings indicated that osteocytes and associated 
Gsα signaling play a role in controlling osteoclastogenesis.  
A previous study showed that mice lacking switch associated protein-70 (Swap-70) have 
defects in F-actin rings and the osteoclast cytoskeleton, leading to osteoclast dysfunction (192). 
Another study has reported that Atp6v1c1 (part of the Vacuolar ATPase (V-ATPase) proton pump) 
is highly expressed in osteoclasts and silencing of this gene impaired F-actin ring formation, 
leading to osteoclast dysfunction (193). The v3 integrin has been determined to be a critical 
regulator of the osteoclast cytoskeleton and F-actin ring formation; additionally, v3 deficient 
mice had osteopetrosis (143, 194). Gsα-dependent factors secreted by osteocytes may affect 
regulators of the osteoclast cytoskeleton, including v3, swap-70, and Atp6v1c1, and may impair 




expression and protein levels of v3, swap-70, and Atp6v1c1 in BMNCs treated with osteocyte-
derived CM.  
Our data regarding the effects of osteocytes on osteoclastogenesis is in agreement with 
previous studies that established the concept that osteocytes control osteoclastogenesis (49, 51, 
53). A previous study reported that viable osteocytes secrete factors that suppress osteoclast 
activity whereas apoptotic osteocytes activate osteoclasts and trigger bone resorption (51). 
Similarly, in vivo depletion of osteocytes, using the diphtheria toxin receptor, increased the number 
of osteoclasts (52). Consistent with these results, we found that osteocytes secrete factor(s) that 
promotes osteoclast apoptosis. Another study showed that osteocytes under mechanical loading 
secreted MEPE which upregulated OPG and decreased the RANKL/OPG ratio, leading to 
osteoclast inhibition (49).  
It has been reported that osteocytes are the primary producer of RANKL, which is 
important for osteoclastogenesis and in vivo deletion of RANKL in osteocytes resulted in mice 
with osteopetrosis (35). However, based on proteomic analysis, we did not identify RANKL as a 
secreted factor. Possible explanations for this discrepancy would be that osteocytes secrete small 
amounts of RANKL, which may remain below the detection limit of mass-spec. Additional studies 
are needed to elucidate the role of osteocyte’s RANKL on osteoclastogenesis. In Ocy454 GsαKO 
cells, OPG was upregulated whereas RANKL was downregulated, lowering the RANKL/OPG 
ratio. Interestingly, although RANKL was added to osteoclast cultures, the decrease in osteoclast 
formation and function was still observed. These findings suggest that osteoclast inhibition is not 
mediated via the OPG/RANKL signaling pathway.  
To delineate the osteocyte secretome and to identify factors capable of controlling 




from both Ocy454 GsαCtrl cells and Ocy454 GsαKO cells. Identification and characterization of such 
factors will help not only to understand the mechanisms of how osteocytes regulate myelopoiesis 
and osteoclastogenesis but also develop therapeutic strategies for myeloproliferative diseases and 
osteoporosis. Several Gs-dependent and -independent factors were identified. Among proteins 
we identified, CP, NRP-1, 2M, and GRN were significantly increased in Ocy454 GsαKO CM 
compared to Ocy454 GsαCtrl CM.  
CP is synthesized by the liver and has a role in copper transport in the blood and iron 
metabolism. It was previously reported that increased CP serum levels were associated with acute 
and chronic inflammation and with rheumatoid arthritis (195, 196). Interestingly, DMP1-GsKO 
mice have increased numbers of neutrophils, suggesting the occurrence of inflammation in these 
mice. NRP-1 is a transmembrane glycoprotein that plays a role in the development of the nervous 
system and angiogenesis. NRP-1 acts as a receptor for SEMA3A protein and some isoforms of 
VEGF (197). Increased levels of NRP-1 have been found to be associated with human tumors, 
including brain, prostate, lung, colon, and breast cancers, as well as with tumor metastasis (198, 
199). It has been reported that NRP-1 could be a potential cancer therapy target (199-201). 
Moreover, a previous study showed that SEMA3A binds to NRP-1 and blocks RANKL-induced 
osteoclast differentiation by inhibiting Rho and immunoreceptor tyrosine-based activation motif 
(ITAM) signaling pathways. The same study showed that SEMA3A also supports osteoblast 
differentiation by stimulating the Wnt signaling pathway (152).  Furthermore, Sema3a-KO and 
Nrp-1 knock-in mice presented with severe osteopenia both in cortical and trabecular bone 
associated with an increase in osteoclastogenesis (152). In our study, we identified NRP-1 as an 
osteocyte Gs-dependent secreted protein capable of inhibiting osteoclastogenesis when added to 




We also identified 2M as a Gs-dependent secreted factor. 2M is a part of type I major 
histocompatibility complex that is expressed by most cell types and plays a role in immunity. It 
has been reported that serum levels of 2M were elevated in cases of multiple myeloma and 
lymphoma, suggesting the potential use of 2M as a prognostic indicator of these disorders (202-
204). GRN was also identified as a secreted factor, which is a group of glycosylated proteins with 
7.5 repeats of a highly conserved 12-cysteine granulin/epithelin motif. GRN is expressed in a 
variety of tissues, including hematopoietic cells, macrophages, skeletal muscles, neurons, 
adipocytes, and chondrocytes (205-208). It has been shown that GRN is involved in inflammation, 
tumorigenesis, epithelial proliferation, wound healing, and insulin resistance (205, 209-211).  
Osteocyte-secreted factors significantly decreased in Ocy454 GsαKO CM as compared to 
Ocy454 GsαCtrl CM include COL3α1, SEMA3D, SEMA3C, COL1α1, COL1α2, SEMA3A, IGSF-
10, MMP2, EMILIN2, and TIMP-2. The decrease in secreted collagens (COL1α1, COL1α2, and 
COL3α1) in Ocy454 GsαKO CM is consistent with our previous observations that DMP1-Gs KO 
mice exhibit an osteopenic phenotype. 
The semaphorin family of proteins, which was initially identified in neuronal development 
and guidance, was recently shown to be associated with bone hemostasis. Semaphorin family 
proteins are classified into eight major classes: classes 1 and 2 are found in invertebrates, classes 
3-7 are found in vertebrates, and class V is expressed by viruses. Semaphorin 3 is the secreted 
form of the semaphorin family proteins, which are further divided into several subclasses, 
including SEMA3A, SEMA3B, SEMA3C, SEMA3D, SEMA3E, SEMA3F, and SEMA3G. 
Plexins (PLXN A, B, C, D) and neuropilins (NRP-1 and NRP-2) are the receptors for semaphorins 
(212, 213). SEMA3A is expressed by osteoblasts and osteocytes and plays a role in bone 




has been reported that Sema3A-deficient mice are osteopenic due to suppressed osteoblast-
mediated bone formation and increased osteoclast-mediated bone resorption. Furthermore, 
treatment with CM from Opg knockout osteoblasts inhibited osteoclast formation, suggesting that 
osteoblasts secrete SEMA3A and other factors that inhibit osteoclast formation independently of 
OPG (152). In our study, we found SEMA3A, SEMA3D, and SEMA3C to be osteocyte-secreted 
proteins. Future studies are needed to define the role of semaphorins in osteocytes.  
MMP-2, a factor secreted by osteocytes, has the ability to degrade extracellular matrix. It 
is produced in an inactive form that is then activated by a specific proteinase. It has been reported 
that MMP-2 is important for normal bone and cartilage development (210). MMP-2 deficient mice 
have a disrupted osteocytic canalicular network, a decrease in bone mineral density, abnormally 
long bones and craniofacial growth, and a decrease in osteoblast and osteoclast numbers at a young 
age (214, 215). These results suggest that MMP-2 is crucial for bone development, mineralization, 
and remodeling. We also found TIMP-2 to be an osteocyte-secreted factor that can counteract the 
effect of MMP-2. TIMP-2 has been shown to inhibit endothelial cell proliferation, thereby 
inhibiting angiogenesis (216). Another study reported that TIMP-2 stimulates osteoclastic bone 
resorption. Further studies are needed to examine the role of MMP-2 and TIMP-2 secretion by 
osteocytes (217). We identified Emilin2 as one of the secreted factors. Emilin2 is a component of 
elastic fiber and is highly expressed in elastin-rich tissue, including blood vessel and skin (218). It 
has been reported that Emilin2 is important for normal vascular development (219). We also 
identified IGSF-10 as an osteocyte-secreted protein. A previous study reported that a mutation of 
IGSF-10 in humans was associated with a delay of puberty due to dysregulation of gonadotropin-




Osteocytes also produce other secreted proteins, including M-CSF, OPN, MIF, TGF-, and 
OPG, in a Gs-independent manner. M-CSF plays an important role in proliferation and survival 
of osteoclast precursors and mice lacking M-CSF display an osteopetrotic phenotype and 
hematopoietic abnormalities (126, 221). Another study reported that osteocytes release M-CSF, 
which targets bone remodeling (12). In our study, we showed that osteocytes supported the 
proliferation of BMNCs in part by secreting M-CSF. OPN has been shown to play a role in many 
biological processes, including bone remodeling, macrophage proliferation, chemotaxis, cell 
survival, and anti-apoptosis (222-225). TGF- was identified as an osteocyte-secreted protein and 
it was reported that osteocytes secrete TGF-, which inhibits osteoclastogenesis (53). We also 
found that osteocytes secrete OPG, which negatively regulates osteoclastogenesis by competitive 
binding to the RANK receptor (148, 151). Interestingly, silencing of OPG by shRNA in osteocytes 
still allows for the inhibition of osteoclastogenesis. Possible explanations for this effect could be 
that osteoclast inhibition is independent of the RANK/ RANKL/OPG mechanism or silencing of 
OPG may upregulate alternative osteoclastogenic inhibitors.  
We performed proteomic analysis of Ocy454 GsαCtrl cells and Ocy454 GsαKO cells to 
investigate the molecular mechanisms by which deletion of Gs in osteocytes affects myelopoiesis 
and osteoclastogenesis. Decreased levels of PRKAR2B, CREB1, and CTNNB1 were observed in 
Ocy454 GsαKO cells as compared to the control. Based on IPA analysis, these proteins are involved 
in multiple signaling pathways, indicating that signaling through Gs may utilize multiple 
signaling pathways to regulate bone homeostasis and hematopoiesis.  
One of the limitations in this work was that knocking out a G protein that transduces the 
signal through multiple receptors may yield alterations in multiple signaling pathways. Future 




osteocytes. Another limitation was the use of an osteocyte cell line (Ocy454), which may not fully 
recapitulate physiological osteocytes in vivo. The ultimate validation is to use primary osteocytes, 
but the current techniques are not sufficient enough to isolate and cultivate primary osteocytes. 
Also, the Ocy454 cell line is heterogeneous, containing cells at different stages of maturation. To 
overcome these limitations, we selected Ocy454 clones based on Sost expression. A KO clone that 
expressed high levels of Sost and a control clone that expressed low levels of Sost were selected, 
which resemble Sost expression in wild type and DMP1-Gs KO mice. Moreover, we used an 
additional model, OEBE, to further investigate osteocyte regulation of myelopoiesis and 
osteoclastogenesis. Lastly, the use of label-free quantification in proteomic analysis was another 
limitation in this study. Although the label-free proteomic analysis is a simple workflow, and faster 
and cheaper than labeling methods, it is less accurate in quantification of proteins. As technology 
advances, we would be able to obtain data from unbiased, genome-wide screening to build solid 






In conclusion, we demonstrated that osteocytes secrete factors that promote myeloid cell 
proliferation in a Gsα-dependent manner. We also showed that osteocytes secrete factors that 
promote BMNC and macrophage proliferation in a Gsα-independent manner. We demonstrated 
that osteoclast differentiation and function were suppressed by Gsα-dependent osteocyte-mediated 
secreted factor(s). We also showed that osteocyte-secreted factor(s) promote osteoclast apoptosis 
(Figure 15). We identified NRP-1 as a novel osteocyte-secreted factor capable of inhibiting 
osteoclastogenesis. In addition, we found that M-CSF secreted by osteocytes is responsible in part 
for BMNC proliferation. Future studies are needed to determine the role of osteocytes-mediated 










Figure 15: Schematic representation of the effect of osteocytes-derived factors on  
BMNCs and osteoclasts. 
Osteocytes secrete M-CSF and other Gsα-dependent and independent factors to promote  
monocyte and macrophage proliferation. Osteocytes secrete NRP-1, GRN, and other Gsα- 
dependent factors to inhibit osteoclast differentiation. Osteocytes secrete Gsα-dependent and  
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